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1.0  INTRODUCTION 
 
The metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) catalyzes a very simple 
but essential physiological reaction, carbon dioxide hydration to bicarbonate and 
protons [1–3]. This reaction also occurs without a catalyst but it is too slow. As CO2, 
bicarbonate, and protons are essential molecules/ions in many important physiologic 
processes in all life kingdoms (Bacteria, Archaea, and Eukarya), throughout the 
phylogenetic tree, and relatively high amounts of them are present in different 
tissues/cell compartments of all such organisms; it is no wonder that CAs evolved 
independently at least five times, with five genetically distinct enzyme families known 
to date: the α-, β-, γ-, δ-, and ζ-CAs [1–6]. All of them are metalloenzymes, but 
whereas α-, β-, and δ-CAs use Zn(II) ions at the active site [1, 4], the γ-CAs are 
probably Fe(II) enzymes (but they are active also with bound Zn(II) or Co(II) ions) [5], 
whereas the ζ-class uses Cd(II) or Zn(II) to perform the physiologic reaction catalysis 
[6]. The 3D-fold of the five enzyme classes is very different from each other, as it is 
their oligomerization state: α-CAs are normally monomers and rarely dimers; β-CAs 
are dimers, tetramers, or octamers; γ-CAs are trimers, whereas the δ- and ζ-CAs are 
probably monomers but in the case of the last family, three slightly different active 
sites are present on the same protein backbone which is in fact a pseudotrimer [1–6]. 
Many representatives of all these enzyme classes have been crystallized and 
characterized in detail, except the δ-CAs [1–6]. 
The α-CAs are present in vertebrates, protozoa, algae, and cytoplasm of green 
plants, and in some bacteria [1–3], the β-CAs are predominantly found in bacteria, 
algae, and chloroplasts of both mono- and dicotyledons, but also in many fungi and 
some Archaea [4, 5]. The γ-CAs were found in Archaea and some Bacteria [1, 4, 5], 
whereas the δ- and ζ-CAs seem to be present only in marine diatoms [6].  
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In many organisms these enzymes are involved in crucial physiological processes 
connected with respiration and transport of CO2/bicarbonate, pH, and CO2 
homeostasis, electrolyte secretion in a variety of tissues/organs, biosynthetic reactions 
(such as gluconeogenesis, lipogenesis, and ureagenesis), bone resorption, 
calcification, tumorigenicity, and many other physiologic or pathologic processes 
(thoroughly studied in vertebrates) [1–3, 7–10], whereas in algae, plants, and some 
bacteria they play an important role in photosynthesis and other biosynthetic reactions 
[1, 4, 5, 11]. In diatoms δ- and ζ-CAs play a crucial role in carbon dioxide fixation [6].  
 
 
1.1.0  CATALYTIC MECHANISM OF CAs 
 
The catalytic mechanism of CAs is understood in detail (see after Fig. 1) [1, 2, 12]. 
In all enzyme classes, a metal hydroxide species (L3–M2+–OH) of the enzyme is the 
catalytically active species, acting as a strong nucleophile (at neutral pH) on the CO2 
molecule bound in a hydrophobic pocket nearby [2d]. This metal hydroxide species is 
generated from water coordinated to the metal ion, which is found at the bottom of the 
active site cavity. The active center normally comprises M(II) ions in tetrahedral 
geometry, with three protein ligands (L) in addition to the water molecule/hydroxide 
ion, but Zn(II) and Co(II) were also observed in trigonal bipyramidal or octahedral 
coordination geometries, at least in γ-CAs [5]. In many enzymes, generation of the 
metal hydroxide species from the metal-coordinated water is the rate determining step 
of the catalytic turnover, which for some α- and ζ-CAs achieve kcat/KM values >108 M-
1 s-1, making CAs among the most effective catalysts known in nature [1, 2]. The metal 
ion ligands are three His residues in α-, γ-, and δ-CAs or one His and two Cys 
residues in β- and ζ-CAs [1–6]. Some β-class enzymes have four protein zinc ligands, 
that is, one His, two Cys, and one Asp coordinated to Zn(II) [13].  
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For these enzymes no water coordinated to the metal ion is present at pH values 
<8, as shown in an excellent crystallographic work from Jones’ group on the 
mycobacterial enzymes mtCA 2, encoded by Rv3558c gene and mtCA 1 encoded by 
Rv1284 (Fig. 2) [13].  
However, at pH values >8, a conserved Arg residue in all β-CAs investigated so far 
(belonging to a so- called catalytic dyad) [13] makes  a  salt bridge  with the Asp 
coordinated to Zn(II), liberating the fourth Zn(II) coordination position, which is then 
occupied by an incoming water molecule/hydroxide ion [13]. 
The inhibition and activation of CAs are also well understood processes, with most 
classes of inhibitors binding to the metal center [1–4, 12], and activators binding at the 
entrance of the active site cavity and participating in the proton shuttling between the 
metal ion—bound water molecule and the environment [14]. This leads to the 
enhanced formation of the metal hydroxide, catalytically active species of the enzyme 
[14, 15]. 
 
 
1.1.1  The α-CAs 
 
Sequencing of eukaryotic/prokaryotic genomes, in particular of pathogens causing 
widespread diseases (for example, malaria, tuberculosis, as well as other bacterial 
and fungal infections), has revealed that CAs are also present in these organisms [1, 
3e, 4a, 5]. However, although vertebrates possess only CAs belonging to the α-class, 
such non-vertebrate organisms have enzymes belonging to the same α-CA family as: 
a CAs from protozoan P. falciparum, named (pfCA); a CAs from H. pylori, named 
(hpCA). 
Moreover, 16 different α-CA isoforms were isolated and characterized in 
mammals, where they play important physiological roles, as briefly outlined above.  
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Some of them are cytosolic (CA I, CA II, CA III, CA VII, CA XIII), others are 
membrane-bound (CA IV, CA IX, CA XII, CA XIV and CA XV), CA VA and CA VB are 
mitochondrial, and CA VI is secreted in saliva and milk. Three acatalytic forms are 
also known, the CA-related proteins (CARP), CARP VIII, CARP X, and CARP XI 
which seem to be cytosolic proteins too [1–3]. The mammalian CAs were the first such 
enzymes isolated and studied in detail [1, 12], and many of them are established 
therapeutic targets with the potential to be inhibited or activated to treat a wide range 
of disorders [1–3, 7–10, 12–15].  
The metal ion (which is a Zn2+ ion in all α-CAs investigated up to now) is essential 
for catalysis. X-ray crystallographic data show that the ion is situated at the bottom of 
a 15 Å deep active-site cleft (shown as a pink sphere in the figure 1; left side), and is 
coordinated by three histidine residues (His94, His96 and His119 shown in green in 
the figure) and a water molecule/hydroxide ion. The histidine cluster involved in the 
proton shuttling processes between the active site and the environment, comprising 
residues His64, His4, His3, His17, His15 and His10, is also evidenced. Amino-acid 
residues 92 and 131 involved in the binding of many sulphonamide/ sulphamate 
inhibitors are shown in yellow. The zinc-bound water is also engaged in hydrogen-
bond interactions with the hydroxyl moiety of Thr199, which in turn is bridged to the 
carboxylate moiety of Glu106; these interactions enhance the nucleophilicity of the 
zinc-bound water molecule, and orient the substrate (CO2) in a favourable location for 
nucleophilic attack (figure 1; right side). The active form of the enzyme is the basic 
one, with hydroxide bound to Zn2+ (A). This strong nucleophile attacks the CO2 
molecule that is bound in a hydrophobic pocket in its neighbourhood (the elusive 
substrate-binding site comprises residues Val121, Val143 and Leu198 in the case of 
the human isozyme CA II) (B), leading to the formation of bicarbonate coordinated to 
Zn2+ (C). The bicarbonate ion  is then displaced by a water molecule and liberated into  
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solution, leading to the acid form of the enzyme, with water coordinated to Zn2+ 
(D), which is catalytically inactive. 
 
 
O=C=O + H2O            HCO3- + H+ 
 
 
 
 
 
 
Fig. 1 hCA II active site and Mechanism of action of carbonic anhydrases 
 
To regenerate the basic form (A), a proton transfer reaction from the active site to 
the environment takes place, which may be assisted either by active-site residues 
(such as His64, the proton shuttle in isozymes I, II, IV, VI, VII, IX and XII–XIV  among 
others) or by buffers present in the medium. The process may be schematically 
represented by reactions (2) and (3): 
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H2O 
E–Zn2+-–OH-               E–Zn2+HCO3-               E–Zn2+–OH2 + HCO3-        (2) 
 
E–Zn2+–OH2                E–Zn2+–OH- + H+                                                   (3) 
 
The rate-limiting step in catalysis is reaction 3, that is the proton transfer that 
regenerates the zinc-hydroxide species of the enzyme. In the catalytically very active 
isozymes, such as CA II, IV, VI, VII, IX, XII, XIII and XIV, the process is assisted by a 
histidine residue placed at the entrance of the active site (His64), or by a cluster of 
histidines (figure 1, left side), which protrudes from the rim of the active site to the 
surface of the enzyme, thus assuring efficient proton-transfer pathways. This may 
explain why CA II is one of the most active enzymes known (with a kcat/Km of 1.5 x 
108 M–1 s–1), approaching the limit of diffusion-controlled processes. 
 
 
1.1.2  The β-CAs 
 
In the last years, some scientists have demonstrated that enzymes present in 
other organisms, such as the bacterial ones from Helicobacter pylori [4a], 
Mycobacterium tuberculosis [4d, 13], Brucella suis [16], and many other pathogenic 
bacteria, as well as pathogenic fungi such as Cryptococcus neoformans [17], Candida 
albicans [17], Candida glabrata [18], and Saccharomyces cerevisiae [4c], constitute 
new drug targets with the potential to design anti-infectives (antibacterial, and 
antifungal agents) possessing a new mechanism of action [1]. These enzymes belong 
to the β-CA family, which is not present in humans [1, 4,16–18]. 
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The new found β-CAs have proved to be crucial for the virulence, growth of these 
pathogens [19–20]. The β-CAs posses high CO2 hydration activity comparable to the 
most active α-CA isoforms, but are less strongly inhibited by sulphonamides. The 
principale difference between these enzymes and α-CAs is that β-CAs are usually 
oligomers, generally formed of two or six monomers of molecular weigh 25 to 30 kDa 
each.The Zn (II) ion is essential for the catalysis in both families of enzymes, but its 
coordination is different and rather variable for β-CAs (Fig. 2, 3). 
Infact, from Mycobacterium tuberculosis we can compare the active sites of two β-
CAs; in the (named mtCA 1) enzyme, encoded by the gene Rv 1284, there are two 
cysteinate residues (Cys35, Cys91), an imidazole from a His88 residue and a water 
molecule which coordinate the metal ion, whereas the neighboring Asp37 and Arg39 
residues form a well-defined salt bridge; in the (named mtCA 3) enzyme, encoded by 
gene Rv3588c, the active site is characterized by a residue Asp53, which displaces 
the water molecule and coordinates directly to the zinc ion, thus breaking a potential 
salt link to Arg55 (Fig. 2). 
 
 
A                                                                B 
Fig. 2 Active sites of two  of β-class carbonic anhydrases isoforms, isolated from Mycobacterium 
tuberculosis [13]. Residues involved in metal chelation in mtCA 1 (A) and mtCA 2 (B) are shown. 
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In summary, differences in coordination of the active site metal are observed; in 
mtCA 2 (B), an aspartic acid side chain displaces a water molecule and coordinates 
directly to the zinc ion, thereby closing the zinc coordination sphere and breaking the 
salt link to a nearby arginine that is a feature of mtCA 1 (A). The two β- carbonic 
anhydrases, thus exhibit both of the metal coordination geometries that have 
previously been observed for structures in this family [13]. 
The active site of fungal β-CAs (named Can2) from Cryptococcus neoformans, is 
characterized by a similar metal coordination geometry, in which the catalytic zinc ion 
is coordinated by the side chains of Cys68, His124, and Cys127 (Fig. 3). The fourth 
coordination site is occupied by a water molecule with an oxygen–metal distance of 
2.07 Å. The position of the water molecule is stabilized through a hydrogen bond to 
the conserved residue Asp70, with a short distance of 2.62 Å [4b], indicating a strong 
interaction. Asp70 is part of an Asp/Arg pair (Asp70/Arg72 in Can2) conserved in all β-
CAs sequenced so far. 
 
Fig. 3 Active site of the Carbonic Anhydrase (Can2) isolated from the pathogenic Cryptococcus 
neoformans [4b]. 
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1.2.0 PHYSIOLOGICAL FUNCTION OF CAs 
 
In prokaryotes, CAs possess two general functions: (1) transport of 
CO2/bicarbonate between different tissues of organism; (2) provide carbon 
dioxide/HCO3- for enzymatic reactions [21]. Recently, it has been proved that non-
vertebrate CAs, representative of the α- and β- families in several pathogens, are 
crucial for the growth or virulence [19, 20]. In the aquatic photosynthetic organism, an 
additional role is that of a CO2-concentrating mechanism, which helps overcome 
carbon dioxide limitation in the environment. 
In higher organism, including vertebrates, the physiological function of CAs have 
been widely investigated over the last 70 years [2c, 22, 23].Thus, isozyme I, II, and IV 
are involved in respiration and regulation of the acid/base homeostasis. These 
complex  processes involve both the transport of CO2/bicarbonate between 
metabolizing tissues and excretion sites (lungs, kidneys), facilitated CO2 elimination in 
capillaries and pulmonary microvasculature, elimination of H+ ions in the renal tubules 
and collecting ducts, as well as reabsorption of bicarbonate in the brush border and 
thick ascending Henle loop in kidneys [2c, 23].  
By producing the bicarbonate-rich aqueous humor secretion (mediated by ciliary 
processes isozymes CA II and CA IV) within the eye, CAs are involved in vision, and 
their misfunctioning leads to high intraocular pressure and glaucoma.  
The highly active CA II is abundant in the bone, and is present only in osteoclasts 
at concentrations of the same order of magnitude as those present in the kidneys [24]. 
Its role there is to provide hydrogen ions, formed from the hydration of CO2, to an 
ATP-dependent proton pump, which uses them in the mobilization of calcium  from the  
bone. Thus, CA II is involved in bone development and function, such as 
differentiation of osteoclasts.  
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CAs are involved in the secretion of electrolytes in many other tissues and organs, 
such as: CSF formation, by providing bicarbonate and regulating the pH in the 
choroids plexus; saliva production in acinar and ductal cells [25]; gastric acid 
production in the stomach parietal cells; bile production; pancreatic juice production; 
intestinal ion transport. 
CAs play an important physiological role in: 1) protection of the gastrointestinal 
tract from extreme pH conditions; 2) regulation of pH and bicarbonate concentration in 
the seminal fluid; 3) muscle functions; 4) adaptation to cellular stress [2c, 23, 25]. 
Some CA isozymes are involved in the carboxylation of pyruvate to oxaloacetate 
(mitochondrial isoforms CA VA and VB) and of acetylcoenzyme A to 
malonylcoenzyme A (cytosolic isoform CA II), as shown schematically (Fig 4) [1]; thus 
in fatty-acid biosynthesis and lipogenesis. 
 
Fig. 4 The transfer of acetyl groups from the mitochondrion to the cytosol (as citrate) for the 
provision of substrate for de novo lipogenesis [1]. All steps involving bicarbonate also need the 
presence of CA isozymes: CA VA and CA VB in the mitochondrion and CA II in the cytosol. 
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Some isozymes (CA IX, CA XII) are predominantly in tumor cells and show a 
restricted expression in normal tissues [1, 2, 7, 10]. It has been recently proved that by 
efficiently hydrating carbon dioxide to protons and bicarbonate, these CAs contribute 
significantly to the extracellular acidification of solid tumors, whereas their inhibition 
reverts this phenomenon to a certain extent [7b]. CA IX and XII are overexpressed in 
many such tumors in response to the hypoxia inducible factor (HIF) pathway, and 
research on the involvement of these isozymes in cancer has progressed significantly 
in recent years.  
At present we know that CA IX, is a transmembrane protein involved in solid tumor 
acidification through the HIF-1α activation cascade. CA IX has a very high catalytic 
activity for the hydration of carbon dioxide to bicarbonate and protons, even at acidic 
pH values (of around 6.5), typical of solid, hypoxic tumours, which are largely 
unresponsive to classical chemo- and radiotherapy. Furthermore, in addition to the 
central CA domain, CA IX contain a transmembrane anchor followed by short C-
terminal cytoplasmic tail (Fig. 5). The N-terminal side of CA IX molecule is extended 
with a so-called proteoglycan-like (PG) region that is homologous to keratin sulphate 
attachment domain of a large proteoglycan aggrecan [9g]. 
Thus, CA IX is used as a marker of tumor hypoxia and as a prognostic factor for 
many human cancers. CA IX is involved in tumorigenesis through many pathways, 
such as pH regulation and cell adhesion control. 
The report of the X-ray crystal structure of CA IX [9c], which is a dimeric protein 
with a quaternary structure not evidenced earlier for this family of enzymes (Fig. 6), 
allows for structure-based drug design campaigns of inhibitors against this novel 
antitumor target. 
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Fig. 5 Domain organization of the CA IX protein: SP=signal peptide; PG=proteoglycan-like domain; 
CA=catalytic domain; TM=transmembrane segment; IC=intracellular, cytosolic tail. 
 
 
 
 
 
Fig. 6 Cartoon representation of the CA IX dimeric protein: in green the short intracytosolic tail, in 
yellow the transmembrane region, in blue the CA domain as obtained by X-ray crystallography [9c] 
and in magenta the proteoglycan (PG) domain. 
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2.0  CARBONIC ANHYDRASE INHIBITORS 
 
2.1.0  INHIBITION BY SULFONAMIDES 
 
The recent years saw the discovery of many new chemotypes (such as coumarins 
[27] phenols, fullerenes) showing significant CA inhibitory activity and a novel 
mechanism of action, in addition to the classical sulfonamides and bioisosteres CAIs 
(sulfamates, sulfamides). 
That, prove how dynamic this research field is. The two main classes of CA 
inhibitors (CAIs) are: the metal complexing anions and the unsubstituted sulfonamide 
and their bioisosteres. These inhibitors bind to the Zn2+ ion of the enzyme either by 
substituting the non-protein zinc ligand to generate a tetrahedral adduct (Equation 1) 
or by addition to the metal coordination sphere to generate trigonal-bypiramidal 
species (Equation 2) [2c, 7a–9a, 21, 22, 26]. The unsubstituted sulfonamides and their 
bioisosteres, which are the most important CAIs, bind in the tetrahedral geometry of 
the Zn2+ ion of the enzyme (Fig. 7A), in deprotonated state, with the nitrogen atom of 
the sulfonamide moiety coordinated to Zn2+, while the anions add to the metal 
coordination sphere, generating trigonal-bypiramidal specie , such as the thiocyanate 
adduct shown in figure (Fig. 7B). 
 
E–Zn2+–OH2 + I               E–Zn2+–I + H2O                 (Substitution reaction)             (1) 
 
E–Zn2+–OH2 + I               E–Zn2+–OH2 (I)                  (Addition reaction)                   (2) 
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Tetrahedral adduct                Trigonal-bypiramidal adduct 
(sulfonamides)                            (thiocyanate) 
A                                           B 
 
Fig. 7 Mechanism of inhibition of carbonic anhydrase: A) Unsubstituted sulfonamides bind to the the 
Zn2+ ion of the enzyme by substituting the non-protein zing ligand to generate a tetrahedral adduct. 
B) Anions inhibitors add to the metal coordination sphere, generating trigonal bypiramidal adducts. 
 
 
At present, several X-ray crystallographic structures are available for many 
adducts of the main CAIs classes known, above all those with sulfonamide inhibitors 
and isozymes CA I, II, IV, IX [9c, 22, 28, 29]. Here, it is reported X-ray structure of the 
catalytic domain of CA IX in complex with a classical, clinically used sulfonamide 
inhibitor, acetazolamide (Fig. 8). Generally, in these adducts, the inhibitors bind within 
the enzyme active site, coordinating with the deprotonated sulfonamide moiety to the 
catalytically Zn2+ ion and generally its NH moiety participates in an hydrogen bond with 
the Oy of Thr199. Furthermore, one of the oxygen atoms of the SO2NH2 moiety also 
participate in an hydrogen bond with the backbone NH moiety of Thr199.  
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Fig. 8 Active  site  region  of  the  hCA IX/AAZ  complex, showing  residues  participating  in the  AAZ 
recognition 
 
 
A general pharmacophore (Fig. 9) for the compounds acting as carbonic 
anhydrase inhibitors has been reported by Thiry et al. [30] from the analysis of the CA 
active site and from the structure of the inhibitors described in the literature [2c]. This 
pharmacophore includes the structural elements that are required to be present in the 
compounds in order to act as CA inhibitors. This includes the presence of a 
sulfonamide moiety which coordinates with the zinc ion of the active site of the CA and 
the sulfonamide is attached to a scaffold which is usually a benzene ring. The side 
chain might posses a hydrophilic link able to interact with the hydrophilic part of the 
active site and a hydrophobic moiety which can interact with the hydrophobic part of 
the CA active site. 
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Fig. 9 Structural elements of CA inhibitors in the CA enzymatic active site. 
 
 
The classical CA inhibitors (CAIs) are the primary sulfonamides, RSO2NH2, which 
are in clinical use for more than 50 years as diuretics and systemically acting 
antiglaucoma drugs [1–3, 12]. In fact there are around 30 clinically used drugs (or 
agents in clinical development) belonging to the sulfonamide or sulfamate class, of 
types 1–25, which show significant CA inhibitory activity (Tab. 1) [1]. 
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Tab.1 Structures of carbonic anhydrase inhibitors 1-25 
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In addition to the established role of these CAIs as diuretics and antiglaucoma 
agents, it has recently emerged that they have potential as anticonvulsant, antiobesity, 
anticancer, antipain, and antiinfective drugs [1–3, 12]. However, critical barriers to the 
design of CAIs as therapeutic agents are related to the high number of isoforms in 
humans (i.e., 16 CAs, of which 13 have catalytic activity), their rather diffuse 
localization in many tissues/organs, and the lack of isozyme selectivity of the presently 
available inhibitors of the sulfonamide/ sulfamate type [1–3]. Infact, among derivatives 
1–25 mentioned before, there are no compounds which selectively inhibit some CA 
isoforms with therapeutic value, although their inhibition profiles against the 13 
mammalian isozymes are highly variable and can be used for the structure-based 
drug design of novel generation, isoform-selective inhibitors (inhibition data of 1–25 
against all human (h) CA isoforms are provided in reference) [1]. 
Acetazolamide (1) was the first non mercurial diuretic to be used clinically in 1956. 
The best-studied drug is acetazolamide, which is frequently administered long term 
owing to its efficient reduction of IOP, minimal toxicity and ideal pharmacokinetic 
properties. However, as CAs are ubiquitously expressed in vertebrates, the systemic 
administration of sulphonamides leads to nonspecific CA inhibition and is associated 
with undesired side effects. The development of water-soluble sulphonamide CAIs to 
be used as eye drops began in the 1990s, and by 1995 the first such pharmacological 
agent, dorzolamide (compound 6), was launched [31] by Merck under the trade name 
Trusopt. A second structurally similar compound, brinzolamide (compound 7), has 
also been approved (by Alcon under the tradename Azopt) for the topical treatment of 
glaucoma [31]. Dorzolamide and brinzolamide are potent water-soluble CAIs that are 
sufficiently liposoluble to penetrate the cornea, and may be administered topically as 
the hydrochloride salt (at a pH of 5.5) or as the free base, respectively [31]. 
The two drugs are effective in reducing IOP and show fewer side effects as 
compared with systemically used drugs. Acetazolamide, dorzolamide  or  brinzolamide  
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probably act as local vasodilators, improving blood flow in this organ and consequently 
clearing metabolic waste products and drusen. Vision following such treatment (in 
early phases of the disease) is markedly improved [31, 32]. 
Thus, acetazolamide represents the prototype of a class of pharmacological 
agents with relatively limited therapeutic use, but which played a major role in the 
development of fundamental renal physiology and pharmacology, and in the design of 
many of the current widely used diuretic agents, such as the thiazide and the high-
ceiling (loop) diuretics. Acetazolamide (compound 1), methazolamide (compound 2), 
ethoxzolamide (compound 3) and dichlorophenamide (compound 5) are used to treat 
oedema due to congestive heart failure and for drug-induced oedema [33-34]. 
Thiazide and high-ceiling diuretics, such as trichloromethiazide 19d, chlorthalidone 22, 
indapamide 23, and furosemide 24, have been discovered in the 60s–70s, when little 
was known about the various CA isozymes, and these drugs were considered not to 
interact substantially with the mammalian CAs [29]  
Indisulam (compound 8), a sulfonamide derivative (originally called E7070) with 
powerful anticancer activity, is in phase II clinical trials as anticancer sulfonamide with 
a complex mechanism of action, which involve the inhibition of several enzymes 
including the carbonic anhydrases (CA IX, CA XII), which participate in tumour 
genesis; recently it was also shown to act as a nanomolar inhibitor of CA IX [35].  
Recently, our group reinvestigated their interactions with the 13 catalytically active 
mammalian CAs and reported the X-ray crystal structures of their adducts with hCA II 
[29]. The newly evidenced binding modes of these diuretics may be thus exploited for 
designing better CA II inhibitors as well as compounds with selectivity/affinity for 
various isoforms with medicinal chemistry applications. 
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CA II is the physiologically dominant isoform, which is catalytically highly efficient, 
widespread in many cell types and thus involved in many physiological processes, and 
also easily crystallisable [1, 2d, 36]. Thus, most of knowledge in the design of CAIs 
with pharmacological applications are based on detailed CA II crystallographic studies. 
CA II has been crystallized in adducts with the main classes of inhibitors, 
sulfonamides and their bioisosters [10a, 36-38], anions [39], phenols [40], coumarins 
[27a], and polyamines [41]. Among all these classes of CAIs, the sulfonamides 
continue to be of great interest, considering the many drugs  currently used clinically 
as antibacterial, hypoglycaemic, anti-hypertensive and antiviral and recently as 
anticancer agent [1, 2c, 42]. 
In summary, all the best derivatives, used clinically incorporate in their molecules a 
common chemical motif of aromatic/heteroaromatic sulfonamide and have 
unsubstituted primary sulfonamide moieties acting as effective zinc-binding moieties; 
X-ray crystallography of CA inhibitors in a complex with enzymes, is an important tool 
in drug design of zinc-enzyme inhibitors, using such structures for the rational 
modelling, drug design of more selective and potent  CAIs for several disease 
applications [10a]. 
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3.0  AIM OF THE WORK 
 
The overall aim of the present thesis is to study the interaction between several 
isoforms of carbonic anhydrase from human, bacteria, fungi and new obtained 
sulfonamides derivatives and their bioisosteres. 
The development of more specific agents is required because of the high number 
of isozymes present in the human body as well as the isolation of many new 
representatives of CAs from all Kingdoms. This is possible only understanding in detail 
the catalytic and inhibition mechanism of these enzymes. 
 
 
3.1.0  HUMAN α-CA INHIBITION 
 
The h-CAs control a remarkable range of fundamental physiological processes in 
the organism and various tissue types [2c]. These include acid-base balance, bone 
resorption, calcification, several biosynthetic pathways and a variety of processes 
involving ion, gas and fluid transfer. Recent evidence demonstrates involvement of 
CAs in cell growth and signalling of hypoxia with implication for cancer development 
and progression [8a]. They differ by tissue distribution, localization, kinetic properties, 
sensitivity to inhibitors and presence of CA unrelated domains. Now it is emerging that 
each CA isoform is associated with specific biochemical pathways. According to the 
newest research data, some CAs interact with other proteins to form large complexes 
called metabolons in which they improve the biosynthetic reactions or ion transport 
efficiency. Clearly, carbonic anhydrases are the major players in mammalian 
physiology, but still in many cases  the series of biochemical events are far from being  
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fully elucidated as well as are still unknown the partners of the different isoforms 
associate to many physiological/pathological processes.  
Basic research is still necessary to clarify fundamental physiological processes, 
whose understanding is a prerequisite for approaching diseases. 
A completely new and very promising aspect of CAs physiology has been recently 
found and refers to over expression of some CA isoforms in cells as a consequence of 
reduced oxygen afflux (hypoxia). This situation is frequently met in tumour tissues 
were the fast growing rate favours anoxic conditions. The isoforms over expressed 
(CA IX, CA XII) are membrane located with the active site exposed toward the exterior 
part thus representing a possible target for new therapies and or diagnostic tools. 
It is well known that aberrant expression of CAs and excess of their enzyme 
activity are common in various pathological situations. For example, increased CA II 
activity contributes to glaucoma and osteoporosis, CA II, VII and XIV are suspected to 
participate in neurological disorders including brain oedema and epilepsy, CAII/CA IV 
play a role in kidney dysfunction, CA V appears involved in obesity and CA IX/CA XII 
have been implicated in cancer progression. 
Therefore, the control of the activity of isoforms involved in a particular disease 
represents a promising therapeutic option. 
Inhibitors of carbonic anhydrase (CAI), mainly of sulphonamide type, are widely 
used as therapeutic agents in the management or prevention of several diseases, but 
they were developed years ago when there was no clear idea of the different and 
specific role played by each isozyme [2c]. 
As a consequence, the available drugs possess many undesired side effects due 
to their lack of selectivity, i.e. indiscriminate inhibition of all CA isozymes. For instance, 
side effects of a recently used antiglaucoma drug, dorzolamide, include contact 
allergy, nephrolitiasis, anorexia, depression and dementia. 
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The advancements in the comprehension of the role of the different CAs isoforms 
and of their spatial localization on one side as well as the progress in the X ray 
crystallographic techniques at high and ultrahigh resolution, and in virtual screening 
methods make more realistic the perspective to design new CA inhibitors with 
differential selectivity toward the different isoforms. Indeed some important 
achievements have been already obtained by some of the groups involved in this 
research field [9c-f]. The main goal is on one hand to improve the knowledge of the 
role of each CAs isoform and, on one hand, to develop inhibitors with higher specific 
isoform selectivity, in order to obtain drugs with reduced side effects and/or new 
diagnostic tools. 
 
 
3.1.1 hCA I and hCA II inhibition 
 
These two isoforms are expressed in several tissues (erythrocytes, eye, GI tract, 
bone osteclasts, kidney, lung, testis, brain) and are included in the group of 
intracellular CAs (cytosolic isoforms). Carbonic anhydrase II is one of the fastest 
enzymes known; it performs major role in respiration and acid-base balance. In 
erythrocytes, it catalyzes the hydration CO2 to HCO3- ions, while in renal tubule it is 
important for the acidification of urine. 
Although CA I appears to contribute about 50% of CO2 hydration activity of most 
mammalian erythrocytes, the available evidence suggest that this isozyme is 
abundant provided; presumably it is present more than CA II; however, the catalytic 
activity of CA I is lower than CA II (about 10% of the catalytic activity). 
The physiological function of the major red cell isozyme, CA I (present in 
concentration of up to 150 µM in the blood) is still unknown. 
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Red blood cell (RBC) CA contributes to CO2 excretion in vertebrates by 
accelerating the rate of conversion between molecular CO2, (the form in which CO2 
can readily diffuse across membranes) and HCO3- (the form in with CO2 is transported 
in the circulation). 
Inhibition of CA has been investigated in the treatment of disease as glaucoma. 
The treatment of this disease with inhibitors of the CAs [2c] is very effective in 
reducing elevated intraocular pressure (IOP) characteristic of this pathology. At 
present are available for clinic use two topical acting inhibitors (dorzolamide DZA and 
Brinzolamide, BRZ) [31], in addition to the classical inhibitors used via systemic  route 
of administration (acetazolamide AAZ, methazolamide MZA, ethoxzolamide EZA, and 
dichlorophenamide DCP) [43].  
However, all these compounds clinically used have a lot of side effects and lack of 
selectivity. 
 
 
3.1.2 hCA VA and hCA VB inhibition 
 
Between the intracellular hCAs are included also two mitochondrial (VA and VB) 
isoforms; the two homologues of CA V possess a leader sequence that target them to 
the mitochondria [44]. These isozymes were shown to be involved in several 
biosynthetic processes, such as ureagenesis [45], gluconeogenesis [46], and 
lipogenesis, both in vertebrates(rodents) as well as invertebrates (locust) [47-49]. 
Indeed, in several important biosynthetic processes involving pyruvate carboxylase, 
acetylCoA carboxylase, and carbamoyl phosphate synthetases I and II, bicarbonate, 
not carbon dioxide is the real substrate of these carboxylating enzymes, and the 
provision of enough  bicarbonate  is  assured  mainly  by  the  catalysis involving  the 
mitochondrial  
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isozyme hCA V (probably assisted by the high activity cytosolic isozyme hCA II) [50-
52]. 
Recently, some of the side-effects observed in obese epileptic patients treated with 
topiramate 9 or zonisamide 10 consisted of a significant weight loss [1, 53-55]. This 
has been rationalized [1] as being due to the lipogenesis inhibition mediated by these 
two agents, which in turn is mediated by inhibition of some CA isozymes involved in 
the carboxylation of pyruvate to oxaloacetate (mitochondrial isoforms CA VA and CA 
VB) and of acetylcoenzyme A to malonylcoenzyme A (cytosolic isoform CA II), as 
already shown, schematically in Figure 4.  
A possible new approach for the treatment and prophylaxis of obesity is based on 
the inhibition of carbonic anhydrases enzymes involved in several steps of de novo 
lipogenesis, both in the mitochondria and the cytosol of cells. Topiramate and 
zonisamide are two antiepileptic drugs that were shown to induce persistent weight 
loss in obese patients, but their mechanism of action is largely unknown. We 
demonstrated strong CA inhibitory properties for these two drugs, by means of kinetic 
studies in solution and X-ray crystallography, against several physiologically relevant 
isoforms, such as CA II, VA and VB. It has been proved that topiramate also inhibits 
lipogenesis in adipocytes, similarly to other sulfonamide CA inhibitors investigated 
earlier. A large number of new sulfonamides have been synthesized and assayed as 
possible inhibitors of CA isoforms involved in lipogenesis. This is the beginning of a 
very new and promising approach for the treatment of obesity [57].  
These compounds have good affinity, but as well as all clinically used drugs 
(Tab.1) [1], are without selectivity. Thus, the objective is to discovery of compounds 
with high affinity and accepted selectivity to understand the role of CA V and the real 
possibility to use CAIs as potential drugs in therapy. The overall effect is a potent 
inhibition of lipogenesis. Presently,  a  combination of topiramate 9  (sustained release  
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form) with phentermine, Qnexa, is in Phase III clinical trials for the treatment of obesity 
[56] making it the first in a class drug, with a novel mechanism of action [1]. 
In previous contributions from our laboratories [54] we have shown that both CA 
VA and CA VB are druggable targets. Rather large libraries of various sulfonamides 
and sulfamates have been assayed as inhibitors of these mitochondrial enzymes, with 
several low nanomolar inhibitors being detected [54]. However, an important drawback 
of most of these compounds is represented by the rather low selectivity for inhibiting 
the mitochondrial CAs over the cytosolic/membrane-bound ubiquitous isoforms such 
as CA I, II (cytosolic) and CA IV (extracellular, membrane-associated isozyme) [1,54]. 
 
 
3.1.3 hCA IX and hCA XII inhibition 
 
CA IX, originally named MN protein, has been the first detected with a monoclonal 
antibody M75 in a human carcinoma cell line HeLa as a cell density-regulated plasma 
membrane antigen [50b]. At that time, this was the ninth mammalian CA identified and 
thus the MN protein was renamed CA IX [50c]. 
Sequence of the cDNA encoding transmembrane isozyme CA XII has been 
published in 1998 by two independent groups [50d-e]. After the identification of these 
two transmembrane isoforms, it has been shown that CA IX is almost exclusively 
associated with tumours, while CA XII is over expressed in some tumour types. 
Carbonic anhydrase (CA, EC 4.2.1.1) IX (CA IX) has recently been shown to be a 
druggble target for imaging and treatment of hypoxic tumours over expressing this 
protein [1, 7b, 9c, 9e-f, 58-62]. Indeed, CA IX is the most strongly over expressed 
gene product, in response to hypoxia in human cancer cells [7b, 9c, 9e-f, 60].This 
enzyme is a multidomain protein [9c] with the CA  subdomain situated  outside the cell  
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and possessing a very high CO2 hydrase catalytic activity [9d], making it a key player 
in the regulation of tumour pH [1, 7b, 9c, 9e-f, 58-62].  
CA IX expression is strongly increased in many types of solid tumours, such as 
gliomas/ependymomas, mesotheliomas, papillary/follicular carcinomas, as well as 
carcinomas of the bladder, uterine cervix, kidneys, esophagus, lungs, head and neck, 
breast, brain, vulva, and squamous/basal cell carcinomas, among others [8b, 50b, 63-
64]. Furthermore, such hypoxic tumours do not generally respond to the classic 
chemo- and radiotherapy [8b, 50b, 63-64]. 
Pouyssegur’s group showed recently [61] that in hypoxic LS174Tr tumour cells 
expressing either CA IX or both CA IX and XII isoforms, in response to a CO2 load, 
both enzymes contribute to extracellular acidification and to maintaining a more 
alkaline resting intracellular pH (pHi), an action that preserves ATP levels and cell 
survival in a range of acidic outside pH (6.0-6.8) and  low  bicarbonate  medium. In 
vivo  experiments  showed that  silencing  of CA IX alone leads to a 40% reduction in 
xenograft tumour volume, with up-regulation of the second gene, that encoding for CA 
XII. Silencing of both CA IX and CA XII gave an impressive 85% reduction of tumor 
growth [61]. Thus, hypoxia-induced CA IX and CA XII are major tumor prosurvival pH-
regulating enzymes, and their combined targeting (i.e., inhibition) held potential for the 
design of anticancer drugs with a novel mechanism of action. The in vivo proof of 
concept that sulfonamide CA IX inhibitors may indeed show antitumor effects, has 
been only very recently published by Neri’s group [62a]. By using membrane-
impermeant derivatives based on the acetazolamide AAZ scaffold to which either 
fluorescein-carboxylic acid or albumin-binding moieties were attached, this group 
demonstrated the strong tumour growth retardation in animals treated for one month 
with these CA inhibitors (CAIs) in mice with xenografts of a renal clear cell carcinoma 
line, SK-RC-52 [62a].  
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Such data show indeed the great promise of tumour growth inhibition with 
sulfonamides acting as CA IX/XII inhibitors, making thus probable the development of 
alternative anticancer drugs based on this approach [1]. The same group also 
reported the proof-of-concept study showing that human monoclonal antibodies 
targeting CA IX can also be used for imaging of hypoxic tumours [62b]. The 
generation of high-affinity human monoclonal antibodies (A3 and CC7) specific to hCA 
IX, using phage technology has been recently reported.  
These antibodies were able to stain CA IX ex vivo and to target the cognate 
antigen in vivo. In one animal model of colorectal cancer studied (LS174T), CA IX 
imaging closely matched pimonidazole staining, with a preferential staining of tumour 
areas characterized by little vascularity and low perfusion [62b].  
The same conclusion has been reached by our group, by using small molecule CA 
IX-selective inhibitors of the type 1 [7b, 9e-f] Fluorescent sulfonamides 1 with a high 
affinity for CA IX have been developed and shown to bind to cells only when CA IX 
protein was expressed and while cells were hypoxic. NMRI-nu mice subcutaneously 
transplanted with HT-29 colorectal tumours were treated with 7% oxygen or with 
nicotinamide and carbogen and were compared with control animals. Accumulation of 
CAI compound 1 was monitored by non-invasive fluorescent imaging. Specific 
accumulation of 1 could be observed in delineated tumour areas as compared with a 
structurally similar non-sulfonamide analogue incorporating the same scaffold 2. 
Administration of nicotinamide and carbogen, decreasing acute and chronic hypoxia, 
respectively, prevented accumulation of 1 in the tumour. When treated with 7% 
oxygen breathing, a 3-fold higher accumulation of 1 was observed. Furthermore, the 
bound inhibitor fraction was rapidly reduced upon tumour re oxygenation [7b, 9e-f]. 
Such in vivo imaging results confirm previous in vitro data demonstrating that CAI 
binding and retention require exposure to hypoxia. Labelled sulfonamide CAIs may 
thus provide a powerful tool to visualize hypoxia response in solid tumours.  
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An important step was thus made towards clinical applicability, indicating the 
potential of patient selection for CA IX-directed therapies [7b, 9e-f]. 
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Fig. 10 AAZ and Fluorescent sulfonamides 1 
 
 
One main draw-back of classical sulfonamide CAIs (such as AAZ) is the lack of 
selectivity for inhibiting CA IX over the other CA isoforms present in humans (fifteen 
isoforms, CA I – XIV, are present in primates and 16 isoforms (i.e., CA I – CA XV in 
other vertebrates) [1]. Thus, it is crucial to explores chemotypes possessing a more 
selective inhibition profile against the target isoforms, e.g., with selectivity for the 
inhibition of the tumor-associted over other CA isoforms.  
Indeed, it has been known that many classes of aromatic/heterocyclic 
sulfonamides and sulfamates have good affinity for this isoform, [1-3, 7–8, 9a-c, 10] 
but generally they do not show specificity for the inhibition of the tumour-associated 
isoform versus the remaining CA isozymes (CA I–VII and XII–XV) found in mammals.  
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Several approaches were reported in the last years for obtaining compounds that 
specifically target the tumour-associated isoforms: (i) the fluorescent sulfonamides 
(such as compound 17 (Tab.1) or see above (type 1), used for imaging purposes and 
for determining the role of CA IX in tumour acidification [1,7, 9e-f]; (ii) the positively 
such as 18 (Tab.1) [65] or negatively charged compounds, which cannot cross plasma 
membranes due to their charged character and thus inhibit selectively only 
extracellular CAs, among which CA IX and XII [1]; (iii) the hypoxia-activatable  
compounds, which exploit the reducing conditions of hypoxic tumours to convert an 
inactive prodrug into an active CAI [66]; (iv) the sugar-containing 
sulfonamides/sulfamates/sulfamides, which due to their highly hydrophilic character do 
not easily cross membranes and thus possess an enhanced affinity for extracellular 
CAs such as CA IX and XII [67]; (v) the nanoparticles coated with CAIs [68] and (vi) 
diverse chemotypes than the sulfonamides and their bioisosteres, such as the 
phenols, protein tyrosine kinase inhibitors, coumarins, fullerenes, and other 
compounds recently investigated as alternative CAIs to the classical types of inhibitors 
[27, 69-71]. 
At present, one of the most interesting compound is named Indisulam. It is a 
sulfonamide derivative with powerful anticancer activity and recently shown to act as 
nanomolar inhibitor of CA IX (in vitro), but without selectivity for some isoforms [35]. 
Indisulam showed in vivo efficacy against human tumour xenograft in nude mice, 
exhibiting a significant antitumour affect and progressing to Phase I and II clinical trials 
for the treatment of solid tumours. Its detailed mechanism of action is not clear, 
involving the inhibition of several enzymes including the carbonic anhydrase (CA IX, 
CA XII). 
Thus, it seem to be necessary to obtain again a better affinity-selectivity profile 
with new compounds to understand the role of CA IX in tumour and the possible 
applications of CAIs as anticancer agents in therapy. 
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3.2.0  BACTERIAL, FUNGAL β-CA INHIBITION 
 
The β-CAs from various fungal [4b-d,17,18] (C. neoformans [4c] , C. albicans [17], 
C. glabrata [18] or S. cerevisiae [4c]) and bacterial [13,16], (M. tuberculosis [13], and 
B. suis [16]) pathogens started to be investigated more recently. Potent inhibitors 
targeting these enzymes were evidenced among sulfonamides, sulfamates, boronic 
acids, and carboxylates [4,13–18].  
However, in vivo the inhibition of the pathogen growth has been observed only for 
some fungi [4b] and bacteria as H. pylori [4a]. In the case of M. tuberculosis no in vivo 
inhibition of growth was evidenced so far, probably due to the difficulty of the inhibitor 
to cross the mycolic acid membrane typical of this bacterium [13] Thus, future work 
should address the permeability of CAIs which in many cases are difficult to be 
delivered at the sites where the enzymes are present in these prokaryotes. On the 
other hand, more bacterial/fungal genomes are being constantly sequenced and the 
finding of novel targets belonging to the various CA families is constant, leading to a 
certain degree of optimism that anti-infectives based on CAIs can be developed. 
The emergence of resistance to the currently used drugs in several human 
pathologies such as Tuberculosis or Candidosis, force to develop of new antiifective 
agents with a novel mechanism of action as isoform-selective CA inhibitors that target 
a particular CA isoform to maximize therapeutic efficacy and to minimize the side 
effects. 
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3.2.1  β-CA from Mycobacterium tuberculosis inhibition 
 
Three β-carbonic anhydrases (CAs, EC 4.2.1.1), (mtCA 1, mtCA 2, mtCA 3) 
respectively encoded by the gene Rv1284, Rv3588c and Rv3273, are present in the 
human pathogen Mycobacterium tuberculosis. These enzymes were cloned and they 
showed appreciable catalytic activity for CO2 hydration. The Rv3273 gene product 
(mtCA 3) is predicted to be a 764 amino acid residues polypeptide, consisting of a 
sulfate transporter domain (amino acids 121-414) in addition to the β-CA mentioned 
above (which is encoded by residues 571-741). All these enzymes were inhibited 
appreciably by many sulfonamides and sulfamates, in the nanomolar-micromolar 
range, whereas some subnanomolar inhibitors were also reported for two of them 
(mtCA 1 and mtCA 3) [13c]. Screening analysis for genes specifically required for the 
mycobacterial growth showed that Rv3588c is required but Rv3273 is not essential for 
the bacterial growth in vivo [20a-b]. However, such findings can not conclusively 
exclude the biological significance of Rv3273 in the survival and/or pathogenicity of M. 
tuberculosis. 
An elegant study by Miltner et al. [20c], identified six invasion-related genes of 
these bacteria. Constitutive expression of the proteins encoded by these genes 
showed significantly increased ability of the bacterial invasion into HEp-2 and HT-29 
intestinal epithelial cells. One of these genes is homologous to M. tuberculosis 
Rv3273, which showed 1.4-1.6 times increase of infected cell numbers by M. avium 
over expressing its gene product. These findings indicate that Rv3273 gene plays a 
role in the bacterial infection process, which is however poorly understood at the 
present time. Thus, inhibition of the three CAs present in this pathogen (mtCA 1, mtCA 
2, mtCA 3) may have relevance for the design of compounds with anti-TB activity 
possessing a novel mechanism of action, devoid of resistance problems encountered 
with classical antibiotics. Rv3273 is predicted  to code  a  bifunctional  transmembrane 
 36 
Fabio Pacchiano “Design, synthesis and biological evaluation of novel carbonic anhydrase inhibitors against mammalian, 
bacterial and fungal isoforms” 
 
protein that consists of an N-terminal sulfate transporter domain and a C-terminal CA 
domain, and we herein demonstrated the significant catalytic activity of this CA 
domain. 
Although it is uncertain how the CA activity of the Rv3273 gene product (mtCA 3) 
works in the bacterial infection process, it is not improbable that effective CAIs may 
prevent bacterial infection [72]. In addition to confirm the sulfate transporter function of 
the amino-terminal end of mtCA 3, further studies are warranted for understanding the 
biological role of this bifunctional transmembrane protein. 
As sulfonamides also efficiently inhibit dehydropteroate synthetase (DHPS), the 
contribution of mtCAs and DHPS inhibition to a possible antimycobacterial action of 
these drugs must be better understood. It has been however proved that mtCAs are 
druggable targets, with a real potential for developing antimycobacterial agents with a 
diverse mechanism of action compared to the clinically used drugs for which many 
strains exhibit multi-drug resistance and extensive multi-drug resistance, although for 
the moment no in vivo inhibition of the bacteria could be evidenced with the presently 
available drugs due to lack of penetrability through the mycolic acid cell wall of M. 
tuberculosis. 
 
 
3.2.2 β-CA from Candida albicans and Candida glabrata inhibition 
 
C.albicans and C. glabrata are important fungal pathogens of humans. In healthy 
individuals C. albicans can be frequently found as a member of the gastrointestinal 
flora and rarely causes infections. However, when individuals become immuno-
suppressed secondary to chemotherapy, AIDS, or even as a consequence of age, C. 
albicans is able to disseminate and cause chronic and potentially life threatening 
systemic disease [73a-b]. 
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One important factor that contributes to C. albicans pathogenicity is its polymorphic 
nature. Indeed, this ascomycete may grow as yeast, pseudohyphal, true hyphal and 
chlamydospore forms. The ability to switch between the yeast and hyphal forms is 
regulated by a wide range of host environmental factors including serum, pH, 
temperature, CO2, and available carbon sources [19a,73]. C. albicans is the 
predominant cause of both superficial and invasive forms of candidosis. 
Candida glabrata is a pathogenic fungi which, similar to C. albicans, possesses a 
recently characterized β-CA isoform (named CgCA) encoded by the nce103 gene [74-
75]. C. glabrata is a common cause of mucosal and invasive, systemic infections, 
accounting for 15% of Candida infections in the general patient population [76-77] 
Furthermore, this pathogen is innately resistant to azole antifungal agents and is less 
susceptible to commonly used in clinical practice antifungals and resistance to these 
agents in C. glabrata has been frequently reported as well [78]. 
The most interesting findings in this field regard the signalling role of CAs that is 
important for the virulence of fungal pathogens such as C. albicans and C. 
neoformans, as identified by Muhlschlegel’s and Heitman’s groups [19]. It has been 
demonstrated that physiological concentrations of CO2/HCO3– induce filamentation in 
C. albicans by a direct stimulation of the adenylyl cyclase activity AC (Cdc35), 
producing a second messenger cAMP. The second protein involved in this 
phenomenon dubbed “CO2 sensing” in pathogenic fungi is a carbonic anhydrase, 
belonging to the β-family encoded by the gene nce103, named here (Nce103p) [1,79]. 
Recently our group has shown that C. glabrata has evolved additional signaling 
mechanisms to permit it to respond to elevated CO2 concentrations, compared to C. 
albicans and C. neoformans [75]. In the same study it has been shown that CA 
expression in C. glabrata is tightly controlled in accordance with the availability of 
bicarbonate, which is essential as a carbon source for the intermediate metabolism 
[75]. 
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4.0 CARBONIC ANHYDRASE ENZYMATIC ACTIVITY: 
SPECTROPHOTOMETRY AND STOPPED FLOW ASSAY 
 
The stopped flow technique is a useful method for following the kinetics of 
reactions in solution (usually in the millisecond time range) in which two reactant 
solutions are rapidly mixed by  being forced through a mixing chamber. The flow of the 
mixed solution along a uniform tube is then suddenly arrested. At a fixed position 
along the tube the solution is monitored (as a function of the time following the 
stopped of the flow) by absorption method with a rapid response (spectrophotometry); 
there is a variable slope (decrease) of the absorption curves of CA II alone and with 
increasing amount of the inhibitor.  
The SX.18MV-R Applied Photophysics stopped-flow instrument directly gives the 
rate value for the reaction (CO2 hydration activity) catalyzed by CAs [80]. 
The equation used by the instrument for the data analysis is the following: 
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We obtain the Amplitude, Rate, Slope and intercept value directly from the 
instrument once chosen the steady state with single exponential function for the 
analysis. 
The main advantages of this method are: 
I) use of CA physiological substrate (saturated CO2 solution) 
II) pH an temperature under physiological conditions 
III) reaction times and reagent amounts reduction 
IV) data reliability 
 
 
4.1.0  REAGENTS 
 
The standard protocol used to carry out all the experiment is reported. 
1. Buffers: 4-(hydroxyethyl)-1-Piperazine-ethanesulphonic acid (HEPES) 10-20 mM as 
buffer, and Na2SO4 anhydrous (to maintain the ionic strength) 10-20 mM at (pH 7.5 for 
α-CAs) or TRIS 10-20 mM as buffer and 10-20 mM NaCl (for maintaining constant the 
ionic strength) at (pH 8.3 for β-CAs). 
2. Phenol red (at the concentration of 0.2 mM) used as indicator (pH 6.8-8.4), working 
at the maximum absorbance of 557 nm. 
3. CO2 solution: obtained by bubbling pure CO2 in bidistilled water solution at 20° C 
until the saturation (usually more than 35 minutes). After that, the solution is kept in a 
tightly closed vessel. If the measurement takes more than 2 hours, another 15 min 
bubbling is performed, in order to maintain the CO2 concentration constant. Depending 
on the temperature the solubility of CO2 in water is known and we can calculate the 
molarity of the substrate. At 20° C this is 17 mM. When working at variable substrate 
concentration is required, this saturated solution is diluted with bidistilled water till the 
desired molarity (CO2 concentration ranged from 1.7-17 mM). 
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4. CA stock solution: enzyme concentrations were prepared in a range between 0.1 
µM (CA I, CA II) to 1 µM (CA V, CA IX, CAXII) depending on the specific activity of the 
isoform (i.e less active they are, more concentrated are the used solutions). 
5. Inhibitor stock solutions: the stock solution (10 mM) were prepared in distilled-
deionized water with 10-20% (v/v) DMSO (which is not inhibitory at these 
concentrations) and dilutions up to 0.01 nM were done thereafter. Four different 
concentrations of inhibitors for each enzyme were used. Inhibitor and enzyme 
solutions were preincubated together for 15 min at room temperature prior to assay, in 
order to allow for the formation of the E-I complex. 
 
 
4.2.0  DATA ANALYSIS 
 
The collected data from the stopped-flow Assay are plotted, as inhibition percentage 
of the enzyme, versus the inhibitors concentrations using a sigmoidal dose-response 
curve (Fig. 11) 
 
 
 
Fig. 11 Sigmoidal dose-response curve of CA II against acetazolamide 
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From the data analysis it is easy measured the IC50 value using a Prism 3.0 Software. 
 
 
 
The simplified Michaelis-Menten equation for steady state is used to calculate the 
specific used inhibitor Ki. 
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5.0  α-CA INHIBITION:  
CAIs FOR DISEASE APPLICATIONS  
 
The effort is being directed toward the development of isoform-selective CA 
inhibitors that target a particular CA isoform to maximize therapeutic efficacy while 
minimizing unwanted side effects. 
 
 
5.1.0  NEW SULFAMIDES AS POTENTIAL ANTIOBESITY DRUGS 
 
Considering the interest in CA VA/VB—selective inhibitors which might be 
developed as antiobesity agents, we explore here a less investigated class of CA 
inhibitors (CAIs) for obtaining compounds targeting the mitochondrial CAs, that is, the 
sulfamides [67a, 81-82]. Furthermore, it has been proved that the sulfamide moety is 
an effective zinc binding group for obtaining CAIs, similarly to the bioisosteric 
sulfonamide and sulfamate ones [81]. 
Here we report the synthesis of 1,3,4-thidiazole sulfamides possessing various 2-
substituents (Scheme 1) [83a-b]. This scaffold has been chosen as it is present in one 
of the most investigated and powerful CAI, acetazolamide AAZ, used clinically since 
1956 [1], and also because its binding to the enzyme is effective, as shown for many 
AAZ derivatives for which the X-ray crystal structure has been resolved in adduct with 
different CA isoforms [38, 84]. Furthermore, all the compounds have been physico-
chemically characterized by 1H, 13C and 19F NMR and Melting points (m.p.) analysis. 
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Scheme 1. Synthesis of 2-substituted-1,3,4-thiadiazole-5-sulfamide 2a — 2j; reagents and 
conditions:(I) t-BuOH, ClSO2NCO, NEt3, CH2Cl2; (II) TFA 95% in CH2Cl2 
 
The general procedure for the preparation of thiadiazole-sulfamides 2 was the 
following: to a solution of 2-substituted-5-amino-1,3,4-thiadiazole 1 in methylene 
chloride and 1.1 equiv of triethylamine was added dropwise a solution of tert-
butoxycarbonylamino sulfonyl chloride (prepared ab initio by reacting 1 equiv of tert-
butanol and 1 equiv of chlorosulfonyl isocyanate in methylene chloride at 0°C) [83a]. 
The mixture was stirred 1 h at room temperature, and then concentrated under 
vacuum. The residue is purified on silica gel column chromatography using ethyl 
acetate-petroleum ether 7–3 as eluent to give the Boc-protected sulfamide in good 
yield (75–80%). This compound was then deprotected using a solution of 
trifluoroacetic acid in methylene choride (1:1, v–v). 
Starting with the commercially available 2-substituted-5-amino-1,3,4-thiadiazoles 
1, which have been sulfamoylated with in situ generated sulfamoyl chloride, by a 
method reported earlier by one of this groups [83a], the sulfamides 2a–j have been 
prepared with excellent yields [83b]. The various substituents in position 2 of the 
heterocyclic ring of the new compounds 2a–j were chosen in such a way as to have a 
rather comprehensive SAR insight for this class of CAIs. Thus, starting with the 
unsubstituted parent compound (R = H, 2a), both aliphatic (Et, t-Bu, etc), aromatic 
(Ph, substituted phenyl, etc) as well as sulfide- and sulfone incorporating such 
moieties have been introduced in this position. X-ray crystallographic data on many 
CA—sulfonamide/sulfamate/sulfamide adducts revealed  that  in  addition  to  the  zinc  
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binding group (a sulfamide one for derivatives 2) and organic scaffold (1,3,4-
thiadiazole for 2), the tails present in CAIs are critical both for the isozyme inhibition 
profile as well as for modulating the physico-chemical properties of such inhibitors, 
which may thus lead to various pharmacological applications [1, 10b, 38, 84–87]. This 
explains the choice of the tail groups present in derivatives 2a–j reported here. 
Inhibition data against five physiologically relevant CA isozymes, that is the cytosolic 
hCA (human CA) I and II, the membrane-associated hCA IV as well as the two 
mitochondrial isoforms hCA VA and VB, are presented in Tab. 2. Three standard 
CAIs, that is, AAZ, ZNS and TPM, have been assayed in the same conditions in order 
to allow a better understanding of the inhibition profile of the new compounds 2a–2j 
investigated here. Data of Tab. 2 allow the following SAR to be evidenced for the new 
sulfamides 2 reported here: 
(i) Against hCA I, the sulfamides 2 showed a moderate-weak inhibitory activity, 
with inhibition constants in the range of 102 nM–7.42 µM, bing thus, with two 
exceptions (compounds 2h and 2j) much weaker inhibitors as compared to the 
clinically used drugs AAZ-TPM (KIs in the range of 56–250 nM). The least active hCA I 
inhibitor was the parent, unsubstituted compound 2a, whereas introduction of various 
substituents in position 2 of the thiadiazole ring enhances activity. The groups leading 
to best activity were 4-methoxyphenyl and methylsulfonyl (2h and 2j). 
(ii) Isozyme hCA II was also weakly inhibited by the new sulfamides 2, with KIs in 
the range of 0.54–1.13 µM, whereas the clinically used drugs were much stronger 
inhibitors of this ubiquitous isoform (KIs in the range of 10–35 nM). It may be observed 
a very flat SAR for sulfamides 2 in inhibiting hCA II, with the nature of groups 
substituting in 2 the thiadiazole ring, having a small influence on the inhibitory power 
(Tab. 2). 
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(iii) Sulfamides 2 act as quite weak inhibitors of the membrane-associated isoforms 
hCA IV, with KIs in the range of 4.32– 10.05 µM, unlike AAZ which is a strong inhibitor 
(KI of 74 nM) but similarly to ZNS and TPM (KIs of 4.90–8.59 µM). 
(iv) Excellent inhibitory properties were evidenced for derivatives 2 against the two 
mitochondrial CA isozymes, hCA VA and hCA VB. Indeed, these compounds showed 
KIs in the range of 4.2–28.3 nM against hCA VA, and of 1.3–74 nM against hCA VB, 
respectively. It may be observed that compounds 2 are much better inhibitors of the 
mitochondrial CAs as compared to the three clinically used drugs (KIs in the range of 
20–63 nM against hCA VA, and of 30–6033 nM against hCA VB, respectively (Tab. 2). 
For hCA VA, the substitution patterns of the heterocyclic ring leading to the best 
inhibitors included the trifluoromethyl, thioethyl-, aryl and methylsulfonyl moieties (KIs 
< 10 nM) whereas the remaining ones generated slightly less effective inhibitors. For 
hCA VB, only three compounds (2a, 2b and 2f) showed KIs > 10 nM, all the other 
substitution patterns leading to derivatives with excellent activity (KIs < 7.5 nM).  
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KI (nM) N0                  R 
 
 
hCA I hCA II hCA IV hCA VA hCA VB 
2a            H 7420 970  8910 28.3 74 
2b            Et 7010 950  8604 18.7 63 
2c            t-Bu 5540 900  8400 10.4        2.8 
2d            CF3 6860 1080  4320  7.3        3.9 
2e            MeS 2400 902  8300 32        2.9 
2f             EtS 1890 1130  7580  9.3 23.1 
2g            Ph 1660 870  5540  9.2        7.5 
2h     4-MeOC6H4 
 
102 540  8760  8.0        1.3 
2i       4-Br-C6H4 
 
5850 820  10050  4.2        4.5 
2j             MeSO2 103 940  6100  8.7        2.7 
AAZ          – 250     12    74 63 54 
ZNS          –      56     35  8590 20 6033 
TPM          – 259      10  4900 63 30 
 
Tab. 2 Inhibition data (KI) of human CA isozymes I, II (cytosolic), IV (membrane-associated), VA and 
VB (mitochondrial), with compounds 2a-j and standard inhibitors (acetazolamide AAZ, zonisamide 
ZNS and topiramate TPM) by a stopped flow, CO2 hydration assay [80]. 
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These are infact the compounds with the best inhibitory activity ever reported 
against the mitochondrial enzymes CA VA and CAVB [83b]. 
(v) Another very interesting property of the newly described sulfamides 2 is related 
to their selective inhibition of the mitochondrial isozymes (CA VA and VB) over the 
cytosolic and membrane-associated isoforms (CA I, II and IV). Especially CA II 
constitutes a problem when designing various CAIs targeting other isozymes, because 
CA II has generally a very high affinity for sulfonamides, sulfamates and sulfamides, 
and it is also a ubiquitous enzyme in vertebrates, including humans [1] As seen from 
data of Tab. 2, the three clinically used compounds mentioned here (but also the other 
CAIs in clinical use) [1] are generally much better CA II than CA VA/VB inhibitors 
(except for zonisamide against CA VA). For example the selectivity ratio of AAZ for 
inhibiting CA VA over CA II is of 0.19, and for inhibiting CA VB over CA II is of 0.22. 
Basically AAZ has a much higher affinity for the cytosolic isoform CA II than for the 
mitochondrial ones. However, all compounds 2 reported here showed a much better 
inhibitory activity against the mitochondrial isozymes than against the cytosolic (or 
membrane-associated) ones. Thus, for example, 2h has a selectivity ratio for inhibiting 
CA VA over CA II of 67.5, and for inhibiting CA VB over CA II of 415. For 2i, these 
ratios are of 195 and of 182, respectively. Thus, these compounds are 67.5–415-times 
better inhibitors of the mitochondrial over the cytosolic isozymes, which is a very 
interesting result, never evidenced earlier for any other class of CAIs [83b]. 
In conclusion, we prepared a small series of 2-substituted-1,3,4-thiadiazole-5-
sulfamides and assayed for the inhibition of five physiologically relevant isozymes, the 
cytosolic CA I and II, the membrane-associated CA IV and the mitochondrial CA VA 
and VB. The new compounds showed weak inhibitory activity against human isoforms: 
a) hCA I with inhibition constants in the range (KIs of 102 nM–7.42 µM); b) hCA II (KIs 
of 0.54–1.13 µM); c) hCA IV (KIs of 4.32–10.05 µM); but were low nanomolar inhibitors  
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of hCA VA and hCA VB, with inhibition constants in the range of 4.2–32 nM and 1.3–
74 nM, respectively.  
Furthermore, the selectivity ratios for inhibiting the mitochondrial enzymes over CA 
II were in the range of 67.5–415, making these sulfamides the first selective CA 
VA/VB inhibitors. 
 
 
5.2.0  NEW SULFONAMIDES  AS POTENTIAL ANTICANCER DRUGS 
 
To the beginning of my thesis work, we decided to prepare new substituted-
pyridinium derivatives of aromatic sulfonamides for two reasons: 1) this type of 
inhibitors were the first non-polymeric membrane-impermeant at low molecular weight 
sulfonamide possessing in vitro and in vivo selectivity for the membrane-bound 
isozyme (CA IV) versus cytosolic isozyme (CA I, II). Due to the salt like character, are 
unable to penetrate through biological membranes as shown by ex vivo (human red 
blood cells as model system) and in vivo studies (perfusion experiments in rats) 
discriminating and selectively inhibiting only CA IV [88]. Recently other representatives 
of these inhibitor’s type have been shown to act selectively versus transmembrane 
isozyme CA IX in vitro [89]; 2) because there is a common project with Bayer Sharing 
Pharma about the possible use as intermediate compounds, leading to the PET 
agents for possible applications in vivo. 
However, considering that there are patenting reasons, thus obviously the secret 
and that at present, none of these compounds obtained with this therapeutic approach 
has been tested in vivo so far, we decided to prepare a new series of ureido-
substituted benzene sulfonamides that have a better bioavailability in comparison with  
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them, and are as diverse ureido-substituted benzene sulfonamides, which have been 
shown earlier to be isoform-selective for some isozyme as CA I [90-91].  
We observed that they may lead to isoform-selective compounds [91]; thus, we 
decided to investigate in detail such derivatives. We report here the synthesis of a 
large series of 4-substituted-ureido-benzenesulfonamides 4-30 prepared by reaction 
of sulfanilamide 3 with aryl/alkyl-isocyanates A1-A27 (Scheme 2). The chemical 
diversity was generated by varying the nature of the starting isocyanate A1-A27. 
Generally Sulfanilamide 3 (2.90 mmols) was dissolved in acetonitrile (20-30 mL) and 
then treated with a stoichiometric amount of isocyanates A1-A27. The mixture was 
stirred at r.t. or heated at 50 °C for 2 h, until completion (TLC monitoring). The heavy 
precipitate formed was filtered-off, washed with diethyl ether (100 ml) and dried under 
vacuo. 
In order to characterize the compounds, 1H, 13C and 19F spectra were recorded 
using a Bruker Advance III 400 MHz spectrometer. The chemical shifts are reported in 
parts per million (ppm) and the coupling constants (J) are expressed in Hertz (Hz). 
Infrared spectra were recorded on a Perkin Elmer Spectrum R XI spectrometer as 
solids on KBr plates. Melting points (m.p.) were measured in open capillary tubes, 
unless otherwise stated, using a Büchi Melting Point B-540 melting point apparatus 
and are uncorrected. 
N
H
N
H
O
R SO2NH2
NH2 SO2NH2 + RNCO
MeCN
3 A1-A27 4-30
 
Scheme 2: Preparation of the 4-ureidosubstituted-benzenesulfonamides 4-30 from sulfanilamide 3 
and isocyanates A1-A27. 
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In a recent work [92], we showed that benzenesulfonamides incorporating 4-
substituted ureido moieties acts as CA II inhibitors with potencies which correlate well 
with the orientation of the R moiety present in the ureido tail of the compounds. 
Indeed, in a congeneric series of five such derivatives investigated as inhibitors of the 
cytosolic isoform hCA II (h =human), it has been observed that the potency varied 
between 3.3 and 226 nM, and by means of X-ray crystallography it has been 
evidenced a very variable orientation of the R-ureido moiety, when the inhibitor was 
bound within the enzyme active site [92].  
A strong correlation has been observed between the binding pattern and R group 
orientation for this small library of compounds [92]. Since, as shown by the X-ray 
crystallographic work [92], it is the nature of the tail R greatly influencing the binding to 
the enzyme (Tab. 3). As the R moiety binds towards the more external part of the 
enzyme active site, where there are major differences in the amino acids constituting 
the active site between the various isoforms [10a], this may also lead to the generation 
of compounds with a better selectivity profile for inhibiting various isoforms. This has 
been infact reported earlier by our group, [91], with the observation that some ureido-
substituted sulfonamides show selective inhibition of isoform hCA I over the dominant 
one hCA II. 
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H
N
H
O
R SO2NH2
 
      4-30 
No R      KI (nM) 
     hCA I  hCA II  hCA IX  hCA XII 
4 Ph      760  3730  575  67.3 
5 PhCH2        92  2200    41.4  49.5 
6 Ph2CH        83  3725    58.8  64.5 
7 4-FC6H4    5080      96    45.1    4.5 
8 4-Cl-C6H4   2150    781    58.0    5.3 
9 4-BrC6H4    1465  1290    69.3    7.9 
10 4-IC6H4    5500  2634    24.5    4.3 
11 4-CF3C6H4         9.7  1150      6.2    2.3 
12 3,5-(CF3)2C6H3                  3690      75    53  39 
13 C6F5    2395      50      5.4    5.1 
14 2-MeOC6H4       92  4070  465  61.2 
15 4-AcC6H4      388  1060      5.4    4.6 
16 2-i-PrC6H4         9.0        3.3      0.5    4.2 
17 4-i-PrC6H4   4330  5005  541  49.7 
18 4-n-BuC6H4   5530  2485  376  28.5 
19 4-n-BuOC6H4       11.3        2.1      0.8    2.5 
20 4-n-octyl-C6H4                    536  9600    47.1  52.8 
21 4-NCC6H4       57.0      64.7      6.0    6.5 
22 2-NCC6H4       10.9        2.4      0.3    4.6 
23 4-PhOC6H4     604      85    69.1    7.1 
24 2-PhC6H4                  1170        9.7    65.7  65.1 
25 3-O2NC6H4       23.4      15      0.9    5.7 
26 4-MeO-2-MeC6H3                      89.2  3310                   73.3    6.0 
27 9H-fluoren-2-yl                  1700    908   102  55.4 
28 cyclopentyl     470    226       7.3    7.0 
29 3,5-Me2C6H3   6530  1765       6.9    6.2 
30 indan-5-yl         9.8        8.9       7.0    2.5 
- AAZ      250      12     25    5.7 
 
Tab.3 Inhibition of hCA I, II (cytosolic isoforms) and hCA IX and XII (transmembrane, tumor-
associated enzymes) with ureido sulfonamides 4-30 and acetazolamide AAZ as standard [80] 
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As shown in Scheme 2 and Tab 3, a large variety of aromatic and aliphatic R 
moieties have been incorporated in the new CAIs 4-30 reported here, in order to have 
an extensive structure-activity relationship (SAR) insight regarding their interactions 
with various CA isoforms with medicinal chemistry relevance.  
The inhibition data of four physiologically relevant α -CA isoforms with compounds 
4-30 and acetazolamide (5-acetamido-1,3,4-thiadiazole-2-sulfonamide, AAZ, a 
clinically used drug) are presented before in (Tab. 3); hCA I and II (cytosolic, 
widespread enzymes) as well as hCA IX and XII (transmembrane, tumor-associated 
CAs) have been included in this study due to their relevance as targets/offtargets 
when developing CAIs. Indeed, CA II for example is the drug target for developing 
antiglaucoma CAIs [1, 58, 59], but it is an offtarget when considering CA IX/XII 
inhibition [1, 7b, 9c,e,f, 58, 59]. In this latter case, only the transmembrane, tumor-
associated isozymes (IX and XII) should be inhibited, as CA II may have the function 
of housekeeping enzyme, and its inhibition may lead to side effects [1, 7b, 9c,e,f, 58, 
59].  
The following SAR can be observed from data of Tab 3, for the series of ureido-
sulfonamides 4-30 investigated here: 
a) the slow cytosolic isoform hCA I was inhibited by compounds 4-30 with a very 
variable potency, with inhibition constants in the range of 9.0 – 5530 nM. Potent hCA I 
inhibition has been observed with the following compounds: 11, 16, 19, 22, and 30. 
These compounds incorporate 2- or 4-substuted phenyl moieties (such as 4-
trifluoromethylphenyl, 2-isopropylphenyl, 4-n-butoxyphenyl, and 2-cyanophenyl), 
except 30 which possesses an indane moiety. It is thus clear, as in the 
crystallographic work reported earlier [92] for 5 of the 27 derivatives reported here, 
that the nature of the (R) moiety substituting the second ureido nitrogen is the 
determining factor  in controlling the inhibitory power, probably due  to the  flexibility  of  
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the ureido linker and the possibility of this moiety to orientate in different subpockets of 
the active site cavities of these enzymes investigated CA isoforms. 
Indeed, a number of these derivatives, including 5, 6, 14, 4, 25 and 26 behaved as 
medium potency hCA I inhibitors with KIs in the range of 23.4 – 92 nM. Again the 
nature of the R moieties present in these compounds was rather variable (benzyl, 
diphenylmethyl and range of 388 – 5530 nM. AAZ is similar to these compounds, with 
an inhibition constant of 250 nM against hCA I (Tab. 3). 
(b) the second offtarget isoform, the cytosolic hCA II has also been inhibited with 
potencies ranging from the low nanomolar to the micromolar by ureidosulfonamides 4-
30 (Tab. 3). Thus, compounds 16, 19, 22, 24 and 30 were very potent hCA II 
inhibitors, with KIs in the range of 2.1 – 9.7 nM. These derivatives incorporate 2- or 4-
substituted phenyl moieties or the indane ring. It is interesting to note that 16 and 19 
contain in their molecule the rather bulky, lipophilic i-Pr, n-BuO or biphenyl moieties, 
which one could considered to be too bulky to fit well within the hCA II active site. 
However as shown here and in the crystallographic, preliminary communication (see 
forward the Fig. 12D) [92], the i-Pr moiety of 16 makes hydrophobic contacts in a 
patch within the enzyme active site never seen earlier to accommodate inhibitors, also 
making a stacking with Phe131. This particular binding mode explains thus the 
excellent hCA II inhibitory of 16. However, four other derivatives of the series 
investigated here, i.e., 7, 13, 25 and 28, exploited different binding pockets within the 
enzyme active site (see forward the Fig 13) [92], and also possessed diverse 
inhibitory power. Another series of compounds showed medium potency hCA II 
inhibition, with KIs in the range of 15 – 96 nM. These compounds (7, 12, 13, 21, 23 
and 25) also possess aromatic groups at the second nitrogen ureido group, such as 4-
fluorophenyl, 3,5-di(trifluoromethyl)phenyl, pentafluorophenyl, 4-cyanophenyl, 4-
phenoxyphenyl or 3-nitrophenyl.  
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The remaining derivatives showed lower hCA II inhibitory properties, with KIs in the 
range of 226 – 9600 nM. The least effective hCA II inhibitor was the derivative 
incorporating the long 4-n-octylphenyl moiety (20). 
(c) the tumor-associated hCA IX was generally better inhibited by these 
compounds compared to hCA I and II discussed before, with KIs in the range of 0.3 – 
575 nM. Only few weak hCA IX inhibitor were detected (e.g., 4, 14, 18 and 27), with 
KIs in the range of 102 – 575 nM, whereas all other derivatives presented inhibition 
constants < 100 nM. Compounds such as 11, 13, 15, 16, 19, 21, 22, 25, 28 and 29 
had excellent hCA IX inhibiting properties, with KIs in the range of 0.3 – 7.3 nM.  
Thus, substitution patterns favourable to potent hCA IX inhibition include the 
presence of 4-trifluoromethylphenyl, pentafluorophenyl, 4-acetylphenyl, 2-i-
propylphenyl, 4-n-butoxyphenyl, 2- and 4-cyanophenyl, 3-nitrophenyl, cyclopentyl and 
3,5-dimethylphenyl moieties. It should be however noted that most of the other 
substitution patterns present in the remaining compounds lead to quite effective hCA 
IX inhibitors, with KIs in the range of 24.5 – 73.3 nM. AAZ is an effective hCA IX 
inhibitor too, with a Ki of 25 nM (Tab. 3). 
(d) hCA XII was also effectively inhibited by sulfonamides 4-30, with KIs in the 
range of 2.3 – 67.3 nM. Thus, this is the isoform with the highest affinity for these 
compounds, as all of them are excellent inhibitors. Inhibition constants < 10 nM have 
been observed with a rather large number of compounds, among which 7-11, 13, 15, 
16, 19, 21, 25, 26, 28-30 and AAZ. Thus many substitution patterns lead to very 
effective hCA XII inhibitors in this congeneric series investigated here. 
The excellent inhibition of all CA isoforms investigated here but also the variability 
in inhibitory power for the various members of this congeneric series, are phenomena 
never observed earlier for any class of CAIs investigated in detail, and is probably due 
to the presence of the ureido linker in these molecules, which leads to the binding of 
the compound in quite multiple ways to the enzymes active sites. 
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(e) the selectivity ratio for inhibiting the target over the offtarget isoforms for this 
congeneric series of sulfonamides is rather complex, just because of the factors 
mentioned above. 
However, some interesting findings emerged. For example, compound 15 has a 
selectivity ratio of 71.8 for inhibiting CA IX over CA I and of 196.3 for inhibiting CA IX 
over CA II (the corresponding ratios for inhibiting CA XII over CA I and II are even 
better), being thus a selective inhibitor of the tumour-associated isoforms over the 
cytosolic ones. Compound 25, is a more stronger inhibitor of the cytosolic isoforms 
compared to 15, but has anyhow rather good selectivity ratio for inhibiting the tumor-
associated over the cytosolic isoforms, i.e., of 26 for the inhibition of CA IX over CA I, 
of 16.7 for the inhibition of CA IX over CA II. 
It should be noted that most of the CAIs of sulfonamide type investigated earlier 
contained CONH or SO2NH linkers between the sulfonamide head moiety and the tail, 
instead of the ureido one present in 4-30. These different linkers allow however less 
flexibility for the inhibitor scaffold, and probably this is the reason why most such 
sulfonamides bind in the cannonical hydrophobic pocket of hCA II and also generally 
do not show isoform selectivity [10a, 92,93]. In contrast, for derivatives incorporating 
the ureido linker (of the type 4-30), it has been shown [92] that the substituted ureido 
tails are found in various hydrophobic pockets/regions of the CA II active site in the 
enzyme-inhibitor adduct. As seen from the crystallographic data [92], the torsion 
angles between these two fragments of the scaffold (indicated by orange and blue 
arrows, respectively) of this type of sulfonamides CAI were quite different for the five 
compounds investigated by X-ray crystallography (i.e., compounds 7, 13, 16, 25, 28) 
(Fig.12) [92]. This probably allows the flexibility of the inhibitors to select the 
hydrophobic pocket in such a way as to avoid steric clashes [10a,92,93]. And to make 
as many as possible favorible interactions with amino acid residues within the enzyme  
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cavity. In particular, only the compound 25 (see after Fig 12E) differs from other 
compounds 7, 13, 16, and 28 in that a direct hydrogen bond is observed between the 
inhibitor and the active site, in addition to those linking the sulfonamide to the 
surrounding amino acids.  
This interaction which does not involve  a solvent bridge , is between Gln92 NE2 
and O8 of the inhibitor at the distance of 2.8 Ǻ (Fig. 12E). Again, compound 25 
exhibits nonplanarity with the C5–C4–N7–C8 and C8–N9–C10–C15, torsion angles 
being –33.91° and –19.11°, respectively. This allows the terminal nitro atoms N16, 
O16 and O17 to make hydrophobic contacts with side chain carbon atoms of Ile91, 
Glu69, and Gln92 (see Fig. 12E).  
 
  
 
Fig. 12 Compound 16 (D) and 25 (E) within the enzyme active site of CA II. 
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Fig. 13 View of compound 7 (orange), compound 13 (pink), 16 (yellow), 25 (grey), 28 (cyan) 
superimposed in the active site of CA II.CA II is depicted as a grey surface representation. The 
active site is depicted as a black sphere. The positions of oxygen and nitrogen atoms of the 
compounds are colourated red and blue, respectively. 
 
 
We report a new series of ureido substituted sulfonamides CAIs which possess 
strong affinity for CA IX, an acceptable selectivity profile for inhibiting in vitro the 
tumour associated-isoforms CA IX, CA X II over the cytosolic one CA I, CA II. 
The previous inhibition data were obtained for the purified recombinant catalytic 
domains of CA IX, CA XII and therefore it is difficult to directly anticipate their 
biological effects either in context of living cells in culture or in tumour tissue.  
As recently demonstrated by Svastova et al. and Cecchi et al. some sulfonamide 
derivatives represented by fluorescent-conjugated thioureido-homosulfanilamide, bind 
only to hypoxic MDCK cells that ectopically express CA IX, but neither to CA IX-
positive normoxic cells nor the CA IX-negative MDCK controls. One of the most 
promising compound developed so far is derivative fluorescent sulfonamide 1 [(4-
sulfamoylphenylethylthioureido) fluorescein] (Fig. 10) 
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It was shown to bind only to hypoxic tumour overexpressing the cancer-associated 
isozyme, which makes it an important candidate for imaging purposes of this type of 
cancer [7b, 9e, 94]. This compounds presents a KI against the CA IX f 24 nM and 
shows a membrane-impermeant property assessed through  an ex vivo model of red 
blood cells membranes [94]. This compound was able to reduce the extracellular 
acidification of Madin–Dardy canine Kidney CA IX (MDCK-CA) cells in hypoxia, and 
their effect on the normoxic extracellular pH was negligible. Furthermore, recently it 
has shown in vivo imaging studies (cells in xenograft tumour model) to be an useful 
diagnostic tool for imaging hypoxic tumour [9e], visualizing hypoxia response. 
Thus, considering all these important findings, in the effort directed toward the 
development of isoform-selective CA inhibitors suitable for the management of cancer, 
we decided to investigate some compounds (compouds 7, 10, 13, 15, 16, 25) as 
valuable candidates within this large series, for in vivo studies. Infact, there are still 
many questions that remain to be answered, such as th sensitivity of tumour-
associated carbonic anhydrases to different sulfonamide inhibitors in various cell 
culture setting under different physiological conditions and to in vivo efficacy as 
antitumour drugs. 
A major challenge of modern chemotherapy is the development of drugs that 
selectively target cancer cells, overcome chemoresistant tumor cells, and have limited 
toxic effects. 
Thus, these compouds were evaluated for their possible antitumour/antimetastasis 
activity on human breast cancer cell line (MDA-MB-231), on (4T1) mouse mammary 
tumour cell line, which produces spontaneously metastatis in mice and on (67NR) 
mouse breast tumour cell line, which forms primary tumours in mice without 
metastasis; the six compouds have been selected due to their selective inhibitory 
activity for CA IX, to investigate them against a peculiar tumour cell lines resistant to 
chemotherapeutics and hypoxia in vivo Assays.  
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These are in vivo methods of screening investigative anticancer drugs, biologic 
response modifiers or radiotherapies. Human tumour tissue or cells are transplanted 
into mice or rats followed by tumor treatment regimens. A variety of outcomes are 
monitored to assess antitumor effectiveness. 
CA IX is highly expressed in breast malignancies [95] and studies have 
demonstrated that CA IX and CA XII are variably expressed in breast cancer cell lines 
[8b, 50a, 63a-b]. Furthermore, CA IX is a poor prognostic marker for patients with 
breast cancer [96] and it is significantly associated with distant metastasis [99]. 
Therefore, we have chosen breast cancer as a model malignancy in which to test, in 
vivo, the anti-metastatic activity of some of the CA IX inhibitors described here. 
Specifically, we have used the 4T1 syngeneic mouse mammary tumor model [97]. The 
4T1 cells are highly tumorigenic and metastasize spontaneously to multiple sites in a 
manner similar to that for human breast cancer following orthotopic implantation into 
an immunocompetent host [97,98]. We have shown recently that 4T1 tumors 
overexpress CA IX [99], and that these cells induce CA IX in hypoxia in vitro. These 
attributes make the 4T1 mouse mammary tumor cells a good model in which to 
examine the effects of inhibiting CAIX activity on breast cancer metastasis. Although 
the 4T1 tumor model can be used to evaluate spontaneous metastatic events 
subsequent to tumor implantation and growth, such studies are lengthy and require 
surgical removal of the primary tumor. Because we were interested in evaluating the 
effect of the compounds on metastasis specifically, we elected to test the inhibitors 
using an experimental metastasis approach. We injected 4T1 cells expressing 
luciferase intravenously and assessed the ability of the cells to form lung metastases 
after treating with compounds 15 (MST-109, Figure 14A) and 25 (MST-119, Figure 
15A) using bioluminescent imaging techniques. Mice were treated with the inhibitors 
or equal amounts of vehicle beginning 24 hours post-injection of cells and metastases 
were imaged the day following the final dose of inhibitor. 
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We found that whereas treatment with MST-109 was not able to decrease the 
metastatic burden relative to the vehicle control group (Figure 14B), treatment with 
MST-119 was effective in limiting colonization of the cells in the lungs in a dose-
dependent fashion (Figure 15B). Quantification of the bioluminescent signal revealed 
a statistically significant decrease in the formation of metastases in the mice 
administered MST-119 (Figure 15C), while no significant differences were observed 
among the vehicle and MST-109-treated groups (Figure 14C) [100a]. 
All animal studies and procedures were carried out in accordance with protocols 
approved by the Institution Animal Care Committee at the BC Cancer research Centre 
and the University of British Columbia (Vancouver, BC, Canada). 4T1 cells 
(5x105/mouse) were injected directly into the tail vein of 7-9 week-old female BALB/c 
mice. Metastatic burden was monitored and quantified using bioluminescent imaging 
as previously described [99, 101]. Briefly, Mice were imaged 24 hours following the 
final dose of a given compound. Images showing tumor burden are displayed using a 
log-scale color range and data were quantified using images acquired for 1 minute at 
a binning level of 8. 
Data were analyzed using the contour ROI feature in the Living ImageR software 
(Xenogen). Results were subjected to statistical analysis using the Data Analysis 
ToolPack in Excel software.Two-tailed p values were calculated using Student’s t-test. 
Data were considered significant for p<0.  
For in vivo studies, compound 25 (MST-119) was solubilized in 37.5% PEG400/12.5% 
ethanol/50% saline prior to injection, while compound 15 (MST-109) was solubilized in 
37.5% PEG400/12.5% ethanol/10% Cremophor/40% saline. Drug aliquots were made 
fresh daily from powder. Drugs were administered by i.p. injection using a volume 
of200 µl for a 20 g mouse. Specific dosing schedules are described in the appropriate 
figures.  
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A              compound 15 (MST-109) 
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14. Ureido-sulfonamide MST-109 did not reduce the formation of metastases by 4T1 mammary 
tumor cells. (A) Chemical structure of MST-109. (B) 4T1 cells were injected directly into the tail vein 
of BALB/c mice. Mice then received vehicle or MST-109 starting 24 hours after injection of cells. 
Animals received therapy every day and 5 doses were provided. Bioluminescent images were 
acquired 24 hours after the final dose of inhibitor. (C) Quantification of bioluminescence. n = 4 per 
group. No significant differences were observed among the vehicle inhibitor-treated groups. 
 
 
 
 
 62 
Fabio Pacchiano “Design, synthesis and biological evaluation of novel carbonic anhydrase inhibitors against mammalian, 
bacterial and fungal isoforms” 
 
A               compound 25 (MST-119) 
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15. Ureido-sulfonamide MST-119 inhibits the formation of metastases by 4T1 mammary tumor cells. 
(A) Chemical structure of MST-119. (B) 4T1 cells were injected directly into the tail vein of BALB/c 
mice. Mice then received vehicle or MST-119 starting 24 hours after injection of cells. Animals 
received therapy every other day and 3 doses were provided. Bioluminescent images were acquired 
24 hours after the final dose of inhibitor. (C) Quantification of bioluminescence. n = 4 per group. 
*P<0.05. 
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Furthermore, recently in these pharmacolgical studies, it has been tested the effect 
of an other selective ureido-sulfonamide inhibitor for CA IX (compound 7), on primary 
breast tumor growth (using a highly metastatic variant of the MDA-MB-231 cell line, 
which induce robustly CA IX in hypoxia) [100b]. Therefore, tumor volume 
measurement showed significant inhibition of primary tumor growth in the mice treated 
with the compound MTS-104 (compound 7) compared to vehicle controls (Fig. 16) 
[100b]. Having demonstrated that selective sulfonamide-based compounds inhibit the 
growth of primary breast tumors, we next tested MST-104 for its ability to inhibit 
metastasis formation in the 4T1 experimental metastasis model. Intravenous injection 
of 4T1 cells into mice and subsequent daily treatment of these animals beginning 24 
hours post-injection with MST-104 resulted in inhibition of metastases formation 
(Figure 17A). Quantification of the bioluminescent signal revealed a statistically 
significant decrease in the formation of metastases in the treated mice (Figure 17B).  
 
 
 
Fig.16 MDA-MB-231 LM2-4Luc+ cells were implanted orthotopically into NOD/SCID mice. When 
tumors reached an average of 200 mm3, animals received the indicated doses of MST-104 
(compound 7) daily and tumor growth was monitored. n = 8/group. *P<0.03, **P<0.001. Inset, 
hypoxia-induced CAIX expression by LM2-4Luc+ cells.  
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Compound 7 (MST-104) 
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17. Ureido-sulfonamide MST-104 inhibits the formation of metastases by 4T1 mammary tumor cells. 
(A) 4T1 cells were injected directly into the tail vein of BALB/c mice. Mice then received vehicle or 
MST-104 starting 24 hours after injection of cells. Animals received therapy every day and 5 doses 
were provided. Bioluminescent images were acquired 24 hours after the final dose of inhibitor (B) 
Quantification of bioluminescence. n = 6 per group. *P<0.01 
 
 
These results suggest that CAIX-specific inhibition may be useful in treating 
metastatic disease in breast cancer. These data show that some of the ureido-
sulfonamide inhibitors of CA IX reported here are effective in attenuating formation of 
metastases in a model of aggressive breast cancer. 
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In conclusion, we report here a series of sulfonamides that was prepared by 
reaction of sulfanilamide with aryl/alkyl isocyanates. These ureido-substituted 
benzenesulfonamides showed a very interesting profile for the inhibition of several 
human carbonic anhydrases (hCAs, E.C. 4.2.1.1), such as hCA I, II (cytosolic 
isoforms) and hCA IX and XII (transmembrane, tumor-associated enzymes). Excellent 
inhibition of all these isoforms has been observed with various members of the series, 
depending on the substitution pattern of the urea moiety. Several low nanomolar CA 
IX/XII inhibitors also showing good selectivity for the transmembrane over the 
cytsosolic isoforms have also been discovered. 
One of them, 4-{[(3’-nitrophenyl)carbamoyl]amino}benzenesulfonamide, 
completely inhibited the formation of metastases by the highly aggressive 4T1 
mammary tumor cells at pharmacologic concentrations of 45 mg/kg, constituting thus 
an interesting candidate for the development of conceptually novel antimetastatic 
drugs. 
Therefore, we showed that inhibiting CA IX with selective inhibitors suitable is 
possible to manage the breast cancer in vivo experiments.  
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6.0  β-CA INHIBITION: CAIs AS ANTIINFECTIVE DRUGS 
 
The infection with Mycobacterium tuberculosis and related Mycobacteria affects 
much of the word population, with an estimated 9.2 million new cases each year, of 
which many lead to death. Furthermore, multidrug resistant and extensively multidrug 
resistant tuberculosis (MDR-TB) is present in 50 countries posing serious concern to 
the global healthcare system. Indeed, the combination therapy used to treat TB is 
based on agents developed in the 1960-1980s, with no new drugs launched for the 
past 30 years. At present, there is a huge need for anti-TB drugs with novel 
mechanism of action, and several agents belonging to the fluoroquinolone, 
oxazolidinone, diarylquinoline, and nitroimidazole-oxazole/-oxazine classes are in M. 
tuberculosis genome in 1998 greatly facilitated the identification of possible new drug 
targets which may lead to the development of compounds possessing a new 
mechanism of action and thus resolve the drug resistance problem mentionated 
above. Among the new proteins identified after the M. tuberculosis genome was 
published, there are three carbonic anhydrases (CAs, EC 4.2.1.1) belonging to the β-
class.  
The emergence of resistance to the currently used drugs (e.g. azoles, polyenes, 
caspofungin and amphotericin B), as well as changes in the spectrum of Candida 
infections have led to an increased interest in susceptibility testing of new antifungal, 
possibly possessing a different mechanism of action. 
Thus, the goal is the structure-base design of possible inhibitory molecules 
(isoform-selective CA inhibitors) against new proteins targets, which are in C. albicans 
and Mycobacterium tuberculosis, beeing today a global drug-resistant emergence 
around these eziologic agents of human Candidosis and Tuberculosis. The catalytic 
activity and inhibition with sulfonamides/sulfamates of all these β-class enzymes  from  
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bacterial and fungal parasites have been reported, but very few low nanomolar 
inhibitors were detected so far for most of them [13c,72,102d-e].  
Sulfonamide/sulfamate CAIs targeting various mammalian α-CAs, such as 
acetazolamide 1, dichlorophenamide 2 or sulfanilamide 3, have been in clinical use for 
more than 50 years [1], but such compounds generally show much less effective 
inhibition of the β-class enzymes [102a-c]. Furthermore, they generally do not possess 
the appropriate pharmacological properties (e.g., good penetration through bacterial 
walls/membranes) to effectively impair the growth of many such pathogens (or they 
show weak such properties, as shown by work on H. pylori and B. suis enzymes) [4a, 
16a,b].  
Thus, in order to understand whether β-CAs may constitute drug targets for 
developing antiinfective agents, it is essential to design compounds with different 
affinities and pharmacological properties compared to the classical CAIs of types 1-3. 
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6.1.0  SULFONAMIDES AGAINST CANDIDOSIS AND TUBERCULOSIS 
 
The fungal β-CAs from Candida albicans [19a] and Cryptococcus neoformans [4b, 
17a-c] (as well as the related enzyme present in Saccharomyces cerevisiae) [ 4c, 
102a-c] were also characterized, being shown to be susceptible to inhibition with the 
main classes of CA inhibitors (CAIs), i.e., the inorganic anions and the sulfonamides 
and their bioisosteres [4b,c, 16a,b, 17a-c, 19a, 102a-c].  
Two other β-CAs from Mycobacterium tuberculosis were successfully cloned and 
crystallized by Suarez Covarrubias et al. [12,13] being denominated mtCA1 and mtCA 
2. Our group identified, cloned and characterized the third such enzyme (mtCA 3), 
encoded by the gene Rv3273 [14]. 
Here we report the synthesis and inhibition studies of several β-CAs from fungal or 
bacterial pathogens with a large series of ureido-substituted sulfonamides obtained 
from sulfanilamide 3 as lead molecule. A large series of 4-ureidosubstituted-
benzenesulfonamides 4-30 was prepared by reaction of sulfanilamide 3 with aryl/alkyl-
isocyanates A1-A27 (Scheme 2, pag.48) The chemical diversity of these derivatives 
was generated by varying the nature of the starting isocyanate A1-A27, since, as 
shown by a recent X-ray crystallographic work on five of these derivatives for which 
the structure in complex with the human isoforms hCA II has been reported [92], was 
determined that it is the nature of the R group that greatly influences the binding to the 
enzyme. For compounds 7, 13, 16, 25 and 28 [92] in adduct with hCA II, it has been 
observed that the benzenesulfonamide fragment binds in the usual manner, 
coordinating to the zinc ion as SO2NH- moiety. The phenylsulfamoyl part of the 
inhibitor was superimposable between all these adducts and bound in the usual way 
[10a], filling the middle of the active site cavity [10a, 92]. 
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However the different R moieties present in these compounds were observed to 
bind towards the external part of the enzyme active site, occupying various sub-
pockets, and none of them was superimposable with each other. This phenomenon is 
probably due to the rather flexible nature of the ureido linker connecting the 
benzenesulfonamide with the the R group in this series of compounds, and may also 
explain a fact reported earlier by our group [91] that such ureido-substituted 
sulfonamides (different of the compounds investigated here) may show selective 
inhibition of isoform hCA I over the dominant one hCA II. Normally, it is hCA II having 
higher affinity for sulfonamides compared to hCA I, at least for most of the clinically 
used derivatives [1, 2c, 3a,g, 5b,e, 103]. A large variety of aromatic and aliphatic R 
moieties have been incorporated in the new CAIs 4-30 reported here, in order to 
expand the structure-activity relationship (SAR) insight regarding their interactions with 
various CA isoforms belonging to the β-class. The synthesis of such compounds is a 
one-step process, generally occurring in high yield, being possible to apply it for the 
preparation of a large number of derivatives. It should be noted that most of the CAIs 
of sulfonamide type investigated earlier [1, 2c, 3a,g, 5b,e, 103] contained CONH or 
SO2NH linkers between the sulfonamide head moiety and the R group, instead of the 
ureido one present in 4-30. These different linkers allow less flexibility for the inhibitor 
scaffold, and this is probably the reason why most such sulfonamides bind in the 
cannonical hydrophobic pocket of hCA II and also generally do not show isoform 
selectivity (Tab. 4) [10a, 91, 93]. 
 
N
H
N
H
O
R SO2NH2
 
4-30 
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No R      KI (nM) 
     hCA II  Nce103p  mtCA 1  mtCA 3 
3 - (sulfanilamide)     240  1086  9230  6240 
4 Ph    3730    395  356    758 
5 PhCH2    2200    547   440    717 
6 Ph2CH    3725  3970  4330  6380 
7 4-FC6H4        96      42.1        6.4      53.0 
8 4-ClC6H4      781      62.0        4.8      63.1 
9 4-BrC6H4    1290      45.0        7.5      87.1 
10 4-IC6H4    2634      42.5        6.8      56.4 
11 4-CF3C6H4   1150      61.0      69.3    533 
12 3,5-(CF3)2C6H3                     75      58.5      65.7    481 
13 C6F5        50      38.0        5.0        6.4 
14 2-MeOC6H4   4070    702    473    603 
15 4-AcC6H4    1060      29.1    470      74.6 
16 2-i-PrC6H4         3.3  3450  5610  6850 
17 4-i-PrC6H4   5005    355  5690      57.5 
18 4-n-BuC6H4   2485      49.6  4760      63.7 
19 4-n-BuOC6H4         2.1      50.6      35.2      63.0 
20 4-n-octyl-C6H4   9600      45.9  6500      81.2 
21 4-NCC6H4       64.7      53.5      50.2      64.4 
22 2-NCC6H4         2.4    326    534    463 
23 4-PhOC6H4       85        3.4    560    818 
24 2-PhC6H4                          9.7    297  5590    748 
25 3-O2NC6H4       15      40.1      67.1        6.5 
26 4-MeO-2-MeC6H3   3310      53.2      49.1      70.3 
27 9H-fluoren-2-yl                    908    573    728    370 
28 cyclopentyl     226    565    509    733 
29 3,5-Me2C6H3   1765      65.9    315    768 
30 indan-5-yl         8.9      71.8    486    632 
- AAZ        12    132    481    104 
 
Tab.4 Inhibition of the β-CAs  enzyme (Nce103p) from C. albicans, the mycobacterial enzymes from 
Mycobacterium tuberculosis (mtCA 1 and mtCA 3) and human hCA II with ureido sulfonamides 4-30, 
sulfanilamide 3 and acetazolamide AAZ, by a stopped-flow CO2 hydrase assay [80] 
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We have investigated the inhibition of the dominant, human isoform hCA II 
(offtarget) as well as three β-CAs from pathogenic organisms (fungi and bacteria) with 
derivatives 4-30 reported here (Tab. 4) [4b,19a, 80] The following SAR could be 
observed from data of Tab.4: 
(i) the offtarget isoform, the cytosolic hCA II, was inhibited with potencies ranging 
from the low nanomolar to the micromolar by ureidosulfonamides 4-30. Compounds 
16, 19, 22, 24 and 30 were very potent hCA II inhibitors, with KIs in the range of 2.1 – 
9.7 nM. These derivatives incorporate 2- or 4-substituted phenyl moieties or the 
indane ring. It is interesting to note that 16 and 19 contain in their molecule the rather 
bulky, lipophilic i-Pr, n-BuO or biphenyl moieties, which might be considered too bulky 
to fit well within the hCA II active site. However as shown here and in the 
crystallographic, preliminary communication [92], the i-Pr moiety of 16 makes 
favorable hydrophobic contacts in a patch within the enzyme active site never seen 
earlier to accommodate inhibitors, also participating to a pi stacking with Phe131. This 
particular binding mode explains the excellent hCA II inhibitory properties of 16 (KI of 
3.3 nM). However, four other derivatives of the series investigated here, i.e., 7, 13, 25 
and 28, exploited different binding pockets within the hCA II active site [92], and also 
possessed diverse inhibitory power compared to 16, with inhibition constants in the 
range of 15-226 nM (Tab. 1). Another series of investigated sulfonamides showed 
medium potency hCA II inhibition, with KIs in the range of 15 – 96 nM. These 
compounds (7, 12, 13, 21, 23 and 25) also incorporate aromatic R groups, such as 4-
fluorophenyl, 3,5-di(trifluoromethyl)phenyl, pentafluorophenyl, 4-cyanophenyl, 4-
phenoxyphenyl or 3-nitrophenyl. The remaining derivatives in this series showed lower 
hCA II inhibitory properties, with KIs in the range of 226 – 9600 nM. The least effective 
hCA II inhibitor was the derivative incorporating the long 4-n-octylphenyl moiety (20). It 
should be also noted that sulfanilamide 3 was a medium potency hCA II inhibitor (KI of 
240 nM) whereas acetazolamide 1 a potent one (KI of 12 nM). 
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(ii) the β-CA from C. albicans was inhibited by the ureido-sulfonamides 4-30 with a 
variable potency, with inhibition constants in the range of 3.4 – 3970 nM, compared to 
sulfanilamide 3 which was a weak inhibitor (KI of 1086 nM) and acetazoalmide 1 which 
was a medium potency inhibitor (KI of 132 nM). Thus, strong inhibition has been 
observed for derivatives 7-13, 15, 18-21, 23, 25, 26, 29 and 30, which possessed 
inhibition constants in the range of 3.4 – 71.8 nM. These compounds incorporate 3- or 
4-substituted phenyl moieties as R groups, such as 4-halogenophenyl, 4-
trifluoromethylphenyl, 4-acetylphenyl-, 4-n-butyl/butoxyphenyl, 4-cyanophenyl-, 4- 
phenoxyphenyl-, 3-nitrophenyl-, as well as 3,5- or 2,4-disubstituted-phenyl moieties 
(except 30 which possesses an indane moiety and 13 which possesses the 
pentafluorophenyl moiety). It is obvious that a rather large number of substitution 
patterns lead to effective C. albicans β-CA inhibitors. The best such inhibitor was 23, 
incoporating the elongated 4-phenoxyphenylureido moiety which, with an inhibition 
constant of 3.4 nM, is the best inhibitor of this enzyme ever reported in the literature 
[4b,17c]. Other substitution patterns present in these compounds led to less effective 
inhibitors. For example, derivatives 4-6, 14, 16, 17, 27 and 28, having aryl, aralkyl or 
cycloalkyl R moieties, are weak C. albicans CAIs, with inhibition constants in the range 
of 297 – 3970 nM (Tab. 4). As for hCA II, small variations in the nature of the R moiety 
leads to very different inhibitory properties for this series of compounds, with highly 
effective, medium potency and ineffective CAIs detected in this congeneric series of 
sulfonamides. 
(iii) the mycobacterial enzyme mtCA 1 was very weakly inhibited by sulfanilamide 3 
and weakly by acetazolamide 1, with inhibition constants in the range of 481-9230 nM 
(Tab. 4). However the ureido-benzenesulfonamides 4-30 reported here generally 
showed a better inhibitory action against this enzyme, with KIs in the range of 4.8 – 
6500 nM. Thus, a number of derivatives, such as 7-10, and 13, were the best mtCA 1 
inhibitors in this series, with KIs in the range of 4.8 – 7.5 nM.  
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All of them incorporate 4-halogenosubstituted phenyl or pentafluorophenyl R 
moieties. Another subseries of these sulfonamides, such as 11, 12, 19, 21, 25 and 26, 
showed slightly less effective inhibitory activity, with KIs in the range of 35.2 – 69.3 
nM. They incorporate mono- or disubstituted phenyl R moieties containing 
trifluoromethyl, nitro, cyano, and alkoxy groups. Medium potency inhibition has been 
observed with compounds such as 4, 5, 14, 15, 22, 23, 27-30, which incorporate aryl, 
aralkyl or cycloalkyl R moieties. The least effective inhibitors were 6, 16-18, 20 and 23, 
most of them incorporating rather bulky R groups (diphenylmethyl, 2-i-Pr-phenyl, 4-n-
Bu-phenyl, 4-noctyl- phenyl, etc), which showed micromolar affinity for this enzyme 
(KIs in the range of 4.33 – 6.50 µM). 
(iv) the mycobacterial enzyme mtCA 3 was inhibited by the new compounds 4-30 
reported here with KIs in the range of 6.4 – 6850 nM, whereas the lead 3 and AAZ 
were ineffective and medium potency inhibitors, respectively (KI of 6.24 µM for 3 and 
of 104 nM for 1). The most effective CAIs against this enzyme were 13 and 25, with 
KIs in the range of 6.4-6.5 nM. The incorporate the pentafluorophenyl and 3-
nitrophenyl R moieties, respectively. A rather large groups of compounds showed 
medium potency inhibitory activity against mtCA 3 , with KIs in the range of 53.0 – 87.1 
nM, and they include the halogenophenyl-substituted derivatives 7-10, the 4-
acetylphenyl group of 15, and the alkyl-/alkoxyphenyl or cyanophenyl moities present 
in 17-21. The disubtituted compound 26 also belong to this category. Again a rather 
large number of R moieties lead to highly enhanced β-CA inhibitory properties 
compared to the lead 3, which was a very ineffective inhibitor of this enzyme (Tab. 4). 
Several of the new derivatives were medium potency (4, 5, 11, 12, 14, 22- 24 and 27-
30) or ineffective (6 and 16) inhibitors of the mtCA 3 enzyme. As for the other α- or β- 
CAs investigated here, it may be observed that all types of activities were detected 
against mtCA 3 for the sulfonamides synthesized in this work. 
 
 74 
Fabio Pacchiano “Design, synthesis and biological evaluation of novel carbonic anhydrase inhibitors against mammalian, 
bacterial and fungal isoforms” 
 
(v) the selectivity ratios of the new sulfonamides investigated here, for the 
inhibition of the target versus offtarget CAs is a rather complex issue, due to the 
particular SAR discussed above for each particular enzyme. However, there are 
interesting aspects that may be evidenced. For example, several compounds such as 
16, 22 and 24 showed low nanomolar hCA II inhibitory activity but were much less 
effective as β-CA inhibitors and can be considered as selective for the inhibition of the 
α- versus β-CAs. Sulfonamide 23 on the other hand was a C. albicans CA selective 
inhibitor, with selectivity ratios for inhibiting the fungal enzyme over the mammalian 
one hCA II of 25, and for inhibiting the fungal over mycobacterial enzymes of 164.7 
and of 240.5, respectively.  
An inhibitor which was selective for the mtca 1 enzyme has also been discovered, 
8, which had selectivity ratios for inhibiting mtCA 1 over hCA II of 162.7, for inhibiting 
mtca 1 over the fungal enzyme of 12.9 and for inhibiting mtCA 1 over mtCA 3 of 13.1. 
For mtCA 3 the most selective inhibitor was 25, with selectivity ratios of 2.3 over hCA 
II, of 6.1 over the C. albicans enzyme, and of 10.3 over mtCA 1. These selectivity 
ratios are less high than for the other two investigate β-CAs, but these are the first 
ever reported CAIs showing this interesting profile and may be useful for 
understanding in greater detail the physiological role of some of these enzymes. 
In conclusion, we report here a series of sulfonamides prepared by reaction of 
sulfanilamide with aryl/alkyl isocyanates. The ureido-substituted benzenesulfonamides 
showed a very interesting profile for the inhibition of hCAII and three β-CAs from 
pathogenic fungal or bacterial species. The C. albicans enzyme was inhibited with 
potencies in the range of 3.4 – 3970 nM, whereas the mycobacterial enzymes mtCA 1 
and mtCA 3 with KIs in the range of 4.8 – 6500 nM and of 6.4 – 6850 nM, respectively. 
The structure-activity relationship for this class of inhibitors is rather complex but the 
main features associated with effective inhibition of both α- and each β-CAs 
investigated here have been delineated.  
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The nature of the R moiety substituting the second ureido nitrogen is the 
determining factor in controlling the inhibitory power, probably due to the flexibility of 
the ureido linker and the possibility of the R group to orientate in different subpockets 
of the active site cavity of these enzymes. 
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7.0  CONCLUSIONS 
 
The overall aim of the present thesis was to study the interaction between several 
isoforms of carbonic anhydrase from human, bacteria, fungi with new series of 
sulfonamides and their bioisosteres. 
The development of more specific agents is required because of the high number 
of isozymes present in the human body as well as the isolation of many new 
representatives of CAs from all Kingdoms. This is possible only understanding in detail 
the catalytic and inhibition mechanism of these enzyme. The carbonic anhydrases are 
the major players in mammalian physiology; thus the control of the activity in a 
particular disease represents a promising therapeutic option. 
We obtained the discovery of some different and more specific agents (CAIs). 
Thus, they may be used, on one hand, to improve the knowledge of the role of each 
CAs isoform and, on one hand, to develop carbonic anhydrase inhibitors with higher 
specific isoform selectivity for (CA VA, CA VB, CA IX), in order to have potentially 
drugs with reduced side effects and/or new diagnostic tools for medicinal chemistry 
applications. 
 
 
7.1.0  α-CAs INHIBITION 
 
We began our work synthesizing before bioisosteres (sulfamides) and then 
sulfonamides, analysing the their inhibitory activity versus human carbonic 
anhydrases, which were described with very different subcellular localization and 
tissue distribution.  
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7.1.1  hCA VA and hCA VB inhibition 
 
A possible new approach for the treatment and prophylaxis of obesity is based on 
the inhibition of carbonic anhydrases enzymes involved in several steps of de novo 
lipogenesis, both in the mitochondria and the cytosol of cells. Topiramate and 
zonisamide are two antiepileptic drugs that were shown to induce persistent weight 
loss in obese patients, but their mechanism of action is largely unknown. 
This has been rationalized [1] as being due to the lipogenesis inhibition mediated 
by these two agents, which in turn is mediated by inhibition of some CA isozymes 
involved in the carboxylation of pyruvate to oxaloacetate (mitochondrial isoforms CA 
VA and CA VB) and of acetylcoenzyme A to malonylcoenzyme A (cytosolic isoform 
CA II). 
These compounds (topiramate and zonisamide) have good affinity, but as well as 
all clinically used drugs (Tab.1) [1], are without selectivity. 
Considering the interest in CA VA/VB—selective inhibitors which might be 
developed as antiobesity agents, we explored here a less investigated class of CA 
inhibitors (CAIs) for obtaining compounds targeting the mitochondrial CAs, that is, the 
sulfamides [67a, 81-82]. 
Furthermore, it has been proved that the sulfamide moety is an effective zinc 
binding group for obtaining CAIs, similarly to the bioisosteric sulfonamide and 
sulfamate ones [81]. 
Thus, we prepared a small series of 2-substituted-1,3,4-thiadiazole-5-sulfamides, 
which was prepared and assayed as inhibitors of several carbonic anhydrase (CA, EC 
4.2.1.1) isoforms: the cytosolic CA I and II, the membrane-associated CA IV and the 
mitochondrial CA VA and VB. The new compounds showed weak inhibitory activity 
against hCA I (KIs of 102 nM–7.42 µM), hCA II (KIs of 0.54–1.13 µM) and hCA IV (KIs 
of 4.32–10.05 µM), but were low nanomolar  inhibitors  of  hCA VA  and hCA VB,  with 
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inhibition constants in the range of 4.2–32 nM and 1.3–74 nM, respectively. 
Furthermore, the selectivity ratios for inhibiting the mitochondrial enzymes over CA 
II were in the range of 67.5–415, making these sulfamides the first selective CA 
VA/VB inhibitors. 
Concluding, we discovered compouds with the best inhibitory activity ever reported 
against the mitochondrial CA VA and CA VB. Furthermore they showed an interesting 
selective inhibition profile for the mitochondrial isoforms versus cytosolic and 
membrane-bound isoforms; thus, these results indicate the new synthesized 
sulfamides as useful tools to understand the exact role of the CA VA and CA VB in 
lipogenesis as well as the potentiality of CAIs as antiobesity drugs.  
 
 
7.1.2  hCA I, hCA II, hCA IX, CA XII inhibition 
 
A completely new and very promising aspect of CAs physiology has been recently 
found and refers to over expression of some CA isoforms in cells as a consequence of 
reduced oxygen afflux (hypoxia). This situation is frequently met in tumour tissues 
were the fast growing rate favours anoxic conditions. The isoforms over expressed 
(CA IX, CA XII) are membrane located with the active site exposed toward the exterior 
part thus representing a possible target for new therapies and or diagnostic tools. 
CA IX and XII are overexpressed in many such tumors in response to the hypoxia 
inducible factor (HIF) pathway, and research on the involvement of these isozymes in 
cancer has progressed significantly in recent years.  
Carbonic anhydrase (CA, EC 4.2.1.1) IX (CA IX) has recently been shown to be a 
druggble target for imaging and treatment of hypoxic tumours over expressing this 
protein. 
 79 
Fabio Pacchiano “Design, synthesis and biological evaluation of novel carbonic anhydrase inhibitors against mammalian, 
bacterial and fungal isoforms” 
 
At present we know that CA IX, is a transmembrane protein involved in solid tumor 
acidification through the HIF-1α activation cascade. CA IX has a very high catalytic 
activity for the hydration of carbon dioxide to bicarbonate and protons, even at acidic 
pH values (of around 6.5), typical of solid, hypoxic tumours, which are largely 
unresponsive to classical chemo- and radiotherapy. CA IX is involved in tumorigenesis 
through many pathways, such as pH regulation and cell adhesion control.  
The advancements in the comprehension of the role of the different CAs isoforms 
and of their spatial localization on one side as well as the progress in the X ray 
crystallographic techniques make more realistic the perspective to design new CA 
inhibitors with differential selectivity toward the different isoforms.  
X-ray crystallography of CA inhibitors in a complex with enzymes, is an important 
tool in drug design of zinc-enzyme inhibitors, using such structures for the rational 
modelling, drug design of more selective and potent CAIs for several disease 
applications [10a]. 
Thus, we started our work analysing the α-CA inhbition with a new series of ureido 
substituted benzene sulfonamide derivatives, prepared by reaction of sulfanilamide 
with aryl/alkyl isocyanate. The ureido-substituted benzenesulfonamides showed a very 
interesting profile for the inhibition of several carbonic anhydrases (CAs, E.C. 4.2.1.1) 
such as the human hCA II.  
Recently, our group investigated their interactions with the 4 catalytically active 
mammalian CAs and reported the X-ray crystal structures of five selected compounds 
of this series (4-substituted-ureido-benzenesulfonamides), in complex with hCA II [92]; 
it was determined that it is the nature of the R group (e.g the moiety substituting the 
second ureido nitrogen) that greatly influences the binding to the enzyme. Thus, the 
nature of the R moiety is the determining factor in controlling the inhibitory power, 
probably due to flexibility of the ureido linker and the possibility of the R group to 
orientate in different subpockets of the active site cavity of these enzymes. 
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All the X-ray and in vitro inhibitory activity data collected, can be used for the 
structure-based drug design of other new similar inhibitors as their isomers (3-
substituted-ureido-benzenesulfonamides) related to CAIs class; 6 isomers synthesized 
and tested have already shown to be isoform-selective inhibitors of CA IX (data not 
reported); that to individuate other possible compouds with a different and better 
affinity-selectivity profile for CA IX, CA XII over CA II. 
Due to the structural similarity but different localization and tissue distribution of α-
CA isoforms, these findings can be thus extended also to other classes of CAIs, and 
probably to other CA isoforms less well investigated than CA II, with the possibility of 
designing inhibitors (CAI) with a better selectivity/affinity for various isoforms with 
medicinal chemistry applications. 
At present, CAI mainly of sulfonamides used as therapeutic agents possess many 
undesired side effects due to their lack of selectivity, i.e. indiscriminate inhibition of all 
CA isozymes. One of the most interesting compound is named Indisulam. It is a 
sulfonamide derivative with powerful anticancer activity and recently was shown to act 
as nanomolar inhibitor of CA IX (in vitro), but without selectivity for some isoforms [35]. 
Indisulam showed in vivo efficacy against human tumour xenograft in nude mice, 
exhibiting a significant antitumour affect and progressing to Phase I and II clinical trials 
for the treatment of solid tumours. Its detailed mechanism of action is not clear, 
involving the inhibition of several enzymes including the carbonic anhydrase (CA IX, 
CA XII). 
Thus, in the effort directed toward the development of isoform-selective CA 
inhibitors suitable for the management of cancer we decided to investigate some 
compounds (7, 10, 13, 15, 16, 25), selected considering several parameters as 
aqueous solubility, affinity for CA IX and selectivity ratios for inhibiting CA IX over CA 
II, to evaluate the possible antitumor/antimetastasis activity in vivo breast tumour 
model. 
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In these experiments, the compounds (25) inside the series of ureido-substituted 
sulfonamide CAIs which possess good selectivity for CA IX and CA XII enzyme over 
the cytosolic enzymes, showed excellent in vivo antimetastatic effects in breast cancer 
model. In particular, treating of mice harbouring CAIX-positive 4T1 mammary tumours 
with novel CAIX-specific small molecule inhibitors that mimicked the effects of CAIX 
depletion in vitro resulted in attenuation of primary tumor growth and metastasis 
formation in both spontaneous and experimental models of metastasis, inhibitory 
effects on CAIX-negative tumors. Similar inhibitory effects on primary tumor growth 
were observed in mice harbouring orthotopic tumors comprised of lung metastatic 
MDA-MB-231 LM2-4Luc+ cells. These findings demonstrate that CAIX is vital for 
growth and metastasis of hypoxic breast tumors and is a specific , biomarker for 
breast cancer metastasis 
In conclusion, we report the synthesis of a series of ureido-substituted sulfonamide 
CAIs which possess strong affinity for CA IX, an acceptable selectivity profile for 
inhibiting the tumor-associated isoforms CA IX and XII over the cytosolic enzymes CA 
I and II, as well as excellent in vivo antimetastatic effects in a mice breast cancer 
model. We have indentified a series of ureido-substituted benzenesulfonamides 
potently inhibit carbonic anhydrase IX and show antitumour/antimetastatic activity in a 
breast cancer models. 
These results show how the carbonic anhydrase sulfonamides may be really used 
alone and/or in association with other antitumour agents, in surrounding of multidrug 
resistance to the usually therapies, because they have a different action, which 
answer to the hypoxia, considered the main environmental factor of resistance. 
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7.2.0  β-CA INHIBITION 
 
The emergence of resistance to the currently used drugs in several human 
pathologies such as Tuberculosis or Candidosis, force to develop of new antiifective 
agents with a novel mechanism of action. 
At present, more bacterial/fungal genomes are being constantly sequenced and 
the finding of novel targets belonging to the various CA families is constant, leading to 
a certain degree of optimism that anti-infectives based on CAIs can be developed. 
The development of isoform-selective CA inhibitors that target a particular CA 
isoform could maximize therapeutic efficacy and to minimize the side effects. 
 
 
7.2.1  β-CA from Mycobacterium tuberculosis and C. albicans inhibition 
 
In order to understand whether β-CAs may constitute drug targets for developing 
antiinfective agents, it is essential to design compounds with different affinities and 
pharmacological properties compared to the classical CAIs (SA, AAZ). 
We report a series of sulfonamides prepared by reaction of sulfanilamide with 
aryl/alkyl isocyanates. The ureido-substituted benzenesulfonamides showed a very 
interesting profile for the inhibition of hCAII and three β-CAs from pathogenic fungal or 
bacterial species.  
The C. albicans enzyme was inhibited with potencies in the range of 3.4 – 3970 
nM, whereas the mycobacterial enzymes mtCA 1 and mtCA 3 with KIs in the range of 
4.8 – 6500 nM and of 6.4 – 6850 nM, respectively. flexibility of the ureido linker and 
the possibility of the R group to orientate in different subpockets of the active site 
cavity of these enzymes. 
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We discovered three sulfonamides isoform-selective inhibitors for β-CA (fungal, 
bacterial enzymes) versus α-CA (human enzymes): 
 
• Sulfonamide 23 was a C. albicans CA selective inhibitor, with selectivity ratios 
for inhibiting the fungal enzyme over the mammalian one hCA II of 25, and for 
inhibiting the fungal over mycobacterial enzymes of 164.7 and of 240.5, 
respectively.  
• Sulfonamide 8 which was an selective inhibitor for the mtCA 1 enzyme from 
Mycobacterium tuberculosis; it showed a selectivity ratios for inhibiting mtCA 1 
over hCA II of 162.7, for inhibiting mtCA 1 over the fungal enzyme of 12.9 and 
for inhibiting ntCA 3 over mtCA 3 of 13.1. 
 
• Sulfonamide 25 was the most selective inhibitor for mtCA 3, with selectivity 
ratios of 2.3 over hCA II, of 6.1 over the C. albicans enzyme, and of 10.3 over 
mtCA 1; These selectivity ratios are less high than for the other two investigate 
β-CAs, but these are the first ever reported CAIs showing this interesting profile 
and may be useful for understanding in greater detail the physiological role of 
some of these enzymes. 
 
The structure-activity relationship for this class of inhibitors is rather complex and 
variable. We have delineated the main features associated with effective inhibition of 
both α- and each β-CAs investigated, and understood the motif of this phenomenon. 
Infact, as shown by a recent X-ray crystallographic work on five of these derivatives 
for which the structure in complex with the human isoforms hCA II has been reported 
[92], it was determined that is the nature of the R group (e.g the moiety substituting 
the second ureido nitrogen) that greatly influences the binding to the enzyme.  
 84 
Fabio Pacchiano “Design, synthesis and biological evaluation of novel carbonic anhydrase inhibitors against mammalian, 
bacterial and fungal isoforms” 
 
Thus, the nature of the R moiety is the determining factor in controlling the 
inhibitory power, probably due to flexibility of the ureido linker and the possibility of the 
R group to orientate in different subpockets of the active site cavity of these enzymes. 
In conclusion we synthesized, designed new sulfonamide compounds with 
different affinities, selectivities and pharmacological properties to understand whether 
β-CAs may constitute drug targets to develop antiinfective agents with a new 
mechanism of action. 
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